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Proteolysis Targeting Chimeras (PROTACs) represent an innovative approach to chemical 
intervention into biology, with attractive therapeutic potential. In contrast to protein inhibition, 
PROTACs trigger targeted protein degradation inside cells via hijacking the ubiquitin-
proteasome machinery. PROTACs are bifunctional compounds composed by two small 
molecules connected by a linker; one molecule binds to a protein of interest and the other one 
binds to an E3 ubiquitin ligase. The ligases most commonly recruited are the von Hippel-
Lindau (VHL) protein complex CRL2VHL and the cereblon (CRBN) complex CRL4CRBN. To date, 
different classes of target proteins have been successfully degraded, including epigenetic 
targets such as bromodomain-containing proteins BRD2, BRD3, and BRD4, BRD9, TRIM24, 
SIRT2, PCAF/GNC5, protein kinases, nuclear receptors and E3 ubiquitin ligases to self-
degrade.  
The work described in this thesis is divided into two parts: the first part is about the research 
activity carried out at the University of Dundee, under the supervision of Professor Alessio 
Ciulli, while a second part involves the work done at the Department of Chemical Core 
Technologies, within Nerviano Medical Sciences (Milan), under the supervision of Doctor 
Eduard Felder. 
 
The aim of the project carried out in Ciulli Lab was to investigate PROTAC-mediated 
degradation of BRD7 and BRD9 proteins, subunits of the human SWI/SNF chromatin 
remodelling complexes. These subunits have gained interest as therapeutic target especially in 
hematopoietic cancers, for example supporting growth of acute myeloid leukemia (AML) cells. 
Despite inhibitors able to disrupt the interaction of the BRD7/9 bromodomains are known, their 
cellular activity has remained limited as other non-bromodomain functions of the target remain 
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unaffected. PROTAC molecules able to induce BRD9 degradation would more profoundly 
impact on BRD7 and BRD9 function and therefore could be used as chemical tools to better 
understand its role in BAF complex and in oncogenesis.  
Following analysis of the available co-crystal structures of the individual target and ligase 
proteins with their respective ligands, a library of degraders has been designed and synthesised, 
involving convergent synthetic strategies to conjugate a diverse range of scaffolds and linkers. 
All compounds were tested in vitro against different cancer cell lines and immunoblotting was 
carried out to assess the target degradation profile. VZ185 was found as a highly selective, 
potent and rapid dual BRD7/BRD9 degrader, with slight preference for BRD9 over BRD7. 
Degradation was demonstrated to be dependent upon proteasomal activity, cullin neddylation 
and VHL binding.  
 
The second section of the thesis reports the design, synthesis and biological characterization of 
PROTACs targeting protein kinases, carried out at NMS for one-year stage. With the future 
prospect of extending the development of PROTAC to other targets, it was planned to study a 
literature example, in order to confirm the proof of concept. Amongst those available, we chose 
DAS-6-2-2-6-CRBN, based on a potent tyrosine kinase inhibitor and a CRBN ligand that 
induce degradation of c-ABL and BCR-ABL. Furthermore, we decided to extend the 
development of degraders focusing on how target ligand and linker composition affect efficacy 
and selectivity. The biological evaluation of the synthetized compounds was performed by the 








Modulating protein activity as a mean to control, alleviate and in some cases even cure diseases 
faces a number of challenges in the field of drug discovery. Many of these challenges concern 
with target validation (i.e. the association of a given target to a given disease progression and 
morbidity) and target tractability with synthetic agents i.e. drugs. In the early stage of 
pharmaceutical research, drug hunters typically focus on understanding the function of a 
protein of interest, its link with the diseases states, as well as the prediction of an efficacious 
and safe response in patients.1 Target validation approaches typically involve genetic 
knockdown and knockout using techniques such as antisense oligonucleotides (ASOs), RNA 
interference (RNAi) and CRISPR-Cas9 technologies which affect expression of protein 
levels.2,3 In spite of the great utility of nucleic acid-based strategies in research, their application 
as drug candidates presents many challenges due to their physiochemical properties such as 
narrow bioavailability and poor metabolic stability.4,5 On the other hand, the identification of 
small-molecule inhibitors that phenocopy the outcome from knockdown experiments is 
challenging. Inadequate pharmacokinetic/pharmacodynamics (PK/PD) profiles, off-target 
effects as well as undesired toxicity profiles often emerge as a result of the high-concentrations 
required to achieve and maintain maximal drug efficacy for the duration of a function response. 
On this basis, targeted protein degradation with small molecules has been recently proposed 
and developed as an alternative approach to successfully target protein-causing diseases.6–8 This 
emerging strategy aims to take advantage of the cellular deconstruction machinery to control 
protein homeostasis. Degraders are revolutionary molecules able to chemically knockdown the 
protein of interest at post-translational level through the modulation of the ubiquitin-
proteasome system (UPS). Degraders combine the advantages of genetic knockdown 
techniques and the ADME (absorption, distribution, metabolism and excretion) properties of 
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small molecules.9,10 This thesis focuses on the development and application of bivalent degrader 
molecules, also known as Proteolysis Targeting Chimeras (PROTACs), as a new modality of 
developing chemical tools for a target protein. PROTACs recruit a target protein to an E3 
ubiquitin ligase enzyme, as a way to trigger E3-ligase mediated ubiquitination and subsequent 
proteasomal degradation of the target protein.9,10 This today represents one of the most exciting 
and impactful modality of pharmacological intervention into biology and diseases.6,7 There are 
other approaches to induce protein degradation that have been described in literature, for 
examples approaches were based on the inhibition of chaperone heat-shock protein 90 
(HSP90), as well as cases of serendipitous compound-induced target degradation, for example 
the selective estrogen and androgen receptor down-regulators (SERDs and SARDs, 
respectively) and hydrophobic tagging (HyT).6 However, the mechanisms of these approaches 
are not entirely understood or do not function necessarily via the UPS, and therefore are outside 
the scope of this thesis.  
 
1.1 Ubiquitin-Proteasome System (UPS): an overview 
The ubiquitin-proteasome system (UPS) is a primary selective cellular machinery responsible 
for protein degradation that plays a fundamental role in cellular homeostasis.11,12  
The ubiquitin pathway regulates protein turnover, as initially discovered by Aaron 
Ciechanover, Avram Hershko and Irwin Rose, for which they were awarded the Nobel Prize 
in Chemistry in 2004. The key factor to determine the protein’s fate is protein ubiquitination.11,13 
This post-translation modification is a multi-step process involving the covalent tagging of a 
protein substrate with ubiquitin, leading to subsequent recognition and degradation by the 26S 
proteasome. Ubiquitin (Ub) is a highly conserved 76 amino acid protein which undergoes a 
covalent isopeptide bond between the C-terminal glycine of ubiquitin and the amino group of 
a lysine residue on the substrate protein. The ubiquitination process is the result of consecutive 
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activity of three enzymes: Ub-activating E1 enzyme, Ub-conjugating E2 enzyme and Ub-
ligating E3 enzyme (Figure 1). The human genome encodes two Ub-activating E1 enzymes, 
37 Ub-conjugating E2 enzymes and over 600 Ub-ligating E3 enzymes. The mechanism of the 
ubiquitin-proteasome pathway (Figure 1) starts with the ATP-dependent activation of the 
ubiquitin carboxy-terminal glycine residue following by formation of a reactive thioester bond 
with a cysteine residue on the active site of the E1 enzyme. Then, the activated ubiquitin is 
transferred to an E2 enzyme to form a new thioester bond via a trans-thiolation reaction. 
Finally, the E3 ligase facilitates the formation of the isopeptide bond between the e-amino 
group of a lysine residue of a target protein and the carboxylic functionality of the terminal 
glycine residue of ubiquitin. Ubiquitination is a reversible process through the action of 
deubiquitinase protease enzymes (DUBs) which cleave the isopeptide bond between the 
protein substrate and ubiquitin.14 
 
 
Figure 1. Schematic mechanism of the ubiquitin-proteasome pathway. 
 
Ubiquitin itself can act as acceptor of further ubiquitin molecules because it contains seven 
lysine residues, leading to ubiquitin polymer chain and, thus, increasing the system 
complexity.15 Depending on i) the number of ubiquitin residues, ii) the position of conjugation 
and iii) the layouts of polyubiquitinated chains, different ubiquitination patterns regulates 
protein fate (i.e. subcellular localization, protein activation, proteasome inhibition and 
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lysosomal degradation). Degrading ubiquitin signalling by proteasome mainly occurs for 
proteins tagged with Lys48-linked ubiquitin chains.15  
Owing to the effect of ubiquitination on several biological processes and its deregulation in 
human diseases, targeting the UPS with small molecules has gained significant interest for 
pharmaceutical research.16,17 Initially, the UPS was targeted at the proteasome level, leading to 
the development of several proteasome inhibitors (Figure 2). One of the most studied 
compound is MG132 (or Z-LLL, Myogenics), a potent proteasome inhibitor that belongs to the 
class of peptide aldehydes.18 In recent years, the US Food and Drug Administration (FDA) 
approved the boronic acid borteozomib (VelcadeÒ, Millennium Pharmaceuticals) and 
epoxyketone carfilzomib (KyprolisÒ, Onyx Pharmaceuticals) as proteasome inhibitors for the 
treatment of relapsed and/or refractory multiple myeloma.19,20 Despite the commercial success, 
patients rapidly developed resistance to proteasome inhibitors and those that do respond suffer 
from many toxic side effects associated to the pleiotropic effects of proteasome inhibitors. 
Indeed, the suppression of the entire proteasomal activity in cell prevents degradation of many 
proteins, leading to dangerous effects. An alternative approach would be targeting upstream 
enzymes in the UPS cascade. One way to achieve this is to target enzymes that function on a 
more limited set of substrate proteins, for example the E3 ubiquitin ligases. Small molecule 
inhibitors of E3 ligases could have value in their own right and can provide suitable handles 
for PROTACs. For the purpose of this project, we will describe small molecule ligands of 




Figure 2. Chemical structures of proteasome inhibitors. 
 
1.1.1 E3 ubiquitin ligases 
E3 ubiquitin ligases represent the major class of enzymes in the ubiquitin-proteasome system 
in terms of diversity and members.15 In the last decade, E3 ligases have become attractive targets 
in drug development for their important role in biological process and human disease states.21,22  
Based on their structural domain and their mode of action, E3 enzymes are divided into three 
subclasses: the homologous to E6-associated protein carboxyl terminus (HECT), RING-




 MG132 Bortezomib Carfilzomib
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Figure 3. Types and molecular mechanism of E3 ubiquitin ligases. A) HECT E3 ligase; B) 
RING-between-RING (RBR) E3 ligase; C) and D) RING E3 ligases. 
 
The HECT family receives ubiquitin from an E2 enzyme before transferring it to the substrate, 
leading to a two-step reaction (Figure 3A). HECT E3s have a L-shaped structure, with a flexible 
hinge loop connecting the N-terminus and C-terminus lobes. The N-terminus region binds the 
E2-Ub activated enzyme, then a conserved cysteine residue in the C-terminus lobe forms an 
intermediate thioester bond with the ubiquitin before catalysing substrate ubiquitylation in 
region outside the HECT domain. HECT E3 molecules can be divided into three groups based 
on domain architecture: the Nedd4 family (9 members), the HERC family (6 members) and 
other HECTs (13 members).24  
A similar two-step reaction is conducted by the RBR E3 family, which combines characteristics 
of both HECT and RING E3s (Figure 3B). RBR E3s comprise two RING domains (RING1 
and RING2) separated by an in-between-RING (IBR) domain. While E2 binds to RING1, the 
reactive cysteine catalysing substrate ubiquitination is located in RING2.25 
The RING E3 ligases are the most abundant type of ubiquitin ligases (Figure 3C, D).26 They 
comprise a RING or RING-like domain, responsible for E2 enzyme binding. Upon binding 
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between E2 and E3 enzymes, ubiquitin is directly transferred to the substrate. There are three 
RING E3 subfamilies: monomers, dimers and multi-subunits. The cullin-RING ligase (CRL) 
is the largest family of multi-subunits E3s and comprises a central cullin subunit which binds 
to E2 binding RING domain (RING-box protein- Rbx1 or Rbx2) at the C-terminus and to a 
substrate recognition domain and/or adaptor subunit(s) at the N-terminus.21  
 
1.1.2 Cullin-RING ligase (CRL) 
CRL is the highly diverse class of E3 ligases with over 200 members that mediates up to 20% 
of proteasome-dependent protein degradation.27,28 This class comprises multi-subunit 
organization by using adaptors, receptors, cullin scaffolds and RING-box domains. All these 
subunits are interchangeable and enable to increase variability and complexity to the E3s. 
Seven Cullin proteins (Cul1, 2, 3, 4A, 4B, 5 and 7) with similar structural architecture are 
expressed in human cells.21 Classification of CRLs is based on the type of Cullin protein in the 
complex, i.e. CRL2 refers to CRL E3s containing Cul2.  
The N-terminal domain (NTD) and the C-terminal domain (CTD) of cullin represent important 
structural elements of CRLs. The NTD forms tight interaction with substrate receptors directly 
or via adaptor subunits.21,29 Examples of adaptors are Skp1, Elongin B and Elongin C (EloBC) 
binary complex and damage-specific DDB1 (DDB1), amongst others. The CTD interacts with 
RING-box proteins Rbx1 and Rbx2 which in turn recruit ubiquitin-charged E2 enzyme and 
promote ubiquitin transfer on the substrate. In the CRL2VHL  complex, adaptor EloBC, substrate 
receptor VHL, scaffold Cul2 and RING protein Rbx1 are assembled together to form the 
complex.30 The EloBC adaptor establishes hydrophobic interactions with a conserved helical 
region called VHL-box domain of the substrate receptor VHL. Larger in size compared to 
EloBC and made up of three WD40 b-propeller domains (BPA, BPB and BPC), DDB1 adaptor 
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connect Cul4 to cereblon (CRBN) or DCAF15 in CRL4CRBN and CRL4DCAF15 complexes, 
respectively.21 
Recent work suggests that CRL complexes exist in “on and off” states, due to a significant 
conformational changes induced by neddylation of cullin.31 Neddylation is the covalent 
attachment of the ubiquitin-like protein NEDD8 to a lysine residue in the cullin CTD, necessary 
for CRL activity, catalysed by NEDD8-activating enzyme (NAE). Thereby, NEDD8 pathway 
modulates the ubiquitination kinetics, providing a suitable drug target. Compound MLN4924 
is a potent and selective inhibitor of NAE, currently in clinical trials for the treatment of solid 
tumours and haematological cancer.27 MLN4924 creates a stable complex with NEDD8 which 
blocks the NAE active site, thus suppressing neddylation of cullin and consequently overall 
CRL activity in cell.27  
 
1.1.3 CRL2VHL inhibitors 
CRL2VHL targets the hypoxia-inducible factor 1a (HIF-1a) for polyubiquitination and 
proteasomal degradation.32,33 HIF-1a  transcription factor plays an essential role in oxygen 
homeostasis and tumor angiogenesis.34,35 HIF-1a binds to VHL substrate recognition receptor 
(pVHL) throughout protein-protein interactions (PPIs), which is exquisitely dictated by 
hydroxylation of proline residues in HIF-1a. Under normoxia conditions, HIF-1a  is 
hydroxylated on two proline residues (namely, Pro402 and Pro564) by the prolyl hydroxylase 
domain (PHD) enzymes in an iron- and oxygen-dependent manner.36 Then, hydroxyproline 
residues (Hyp402 and Hyp564) of HIF-1a  are recognized by VHL and targeted for 
degradation. In contrast, under low oxygen levels, PHD catalytic activity is suppressed. HIF-
1a remains unhydroxylated and translocates into the nucleus where it dimerizes with HIF-1b. 
The heterodimer binds to hypoxia response elements (HREs) of HIF-target genes. As result, 
expression of genes linked to oxygen sensing and hypoxic response is induced.37  
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Inhibition of HIF-1a  pathway would be expected to mimic the physiological response to low 
oxygen levels providing therapeutic benefit for many pathological states, as anemia associated 
to cancer chemotherapy and chronic kidney diseases, ischemia, inflammation and 
neurodegeneration.34,38 Several small-molecule PHD inhibitors of clinical relevance have been 
developed, but their poor selectivity could promote off-target effects.39–42 To avoid the unwanted 
side effects of PHD inhibitors, potent inhibitors of the VHL: HIF-1a PPI leading to HIF-
1a stabilization were developed.43 Ciulli and co-workers in collaboration with Crews laboratory 
at Yale University identified a first series of VHL:HIF-1a PPI inhibitors (Figure 4).44–47 VHL 
inhibitors were designed starting from a hydroxyproline fragment, crucial for interaction with 
VHL. A structure-guided and fragment-based medicinal chemistry campaign led to the 
discovery of VH032, bearing optimized binding groups at the left-hand (LHS) and right-hand 
(RHS) sides of the key Hyp core fragment in the molecule (Figure 4). VH032 is a potent 
inhibitor (Kd = 185 nM, measured by ITC) able to disrupt VHL:HIF-1a PPI and to stabilize 
hydroxylated HIF-1a.43,48 Analysis of the crystal structure of VH032 bound to VHL protein 
suggested significant scope to further optimize the inhibitor by modifying the LHS of the 
molecules. Indeed, the acetamide group partially filled the pocket where it is accommodated, 
providing a space to optimize the compound. Medicinal chemistry campaign within the Ciulli 
group at Dundee led to the discovery of VH101 and VH298, bearing a fluoro- and a cyano-
cyclopropyl moiety, respectively (Figure 4).49 VH298 [Kd (ITC) = 90 nM] and VH101 [Kd (ITC) 
= 44 nM] inhibitors showed high binding affinity, good cell permeability and high activity in 
cells.43,49 However, cellular studies revealed a degree of cytotoxicity for VH101 when used at 
high (~100 µM) concentrations.43 Following thorough biophysical and in vitro characterization 
in cell lines, VH298 was shown to be highly active as VHL inhibitor at concentrations greater 
than 10 µM without significant off-target effects or cytotoxicity, driving on-target stabilization 
of HIF-1a and induction of HIF dependent activity and responses in cells.43 Based on this 
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extensive data, VH298 has been elected as novel chemical probe of hypoxic signalling pathway 




Figure 4. VHL ligands optimization throughout medicinal chemistry campaign  
 
1.1.4 CRL4CRBN and CRL4DCAF15 inhibitors 
Thalidomide is infamously known for its teratogenicity that emerged following prescriptions 
in the 1950s as sedative for the treatment of morning sickness in pregnant women. Nowadays, 
the immunomodulatory drugs (IMiDs) thalidomide and its derivatives lenalidomide and 
pomalidomide are widely used for the treatment of multiple myeloma (Figure 5). In particular, 
lenalidomide (marketed as Revlimid® by Celgene) is extensively used as front-line drug for 
the treatment of multiple myeloma and was the top selling cancer drug in 2016.50 Indeed, IMiDs 
were recently found to bind to CRBN, the substrate recognition component of the CRL4CRBN E3 
ubiquitin ligase complex, and to prevent binding with endogenous substrate as MEIS2.51 
However beyond their potential inhibitory role, upon binding to CRBN, IMiDs induce 
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induced protein-protein interactions (PPIs) with the CRBN-IMiDs complex.51–53 These neo-
substrate proteins include members of the IKAROS family transcription factors IKZF1 and 
IKZF3 (also known as Ikaros and Aiolos). Degradation of IKZF1 and IKZF3 forms the basis 
of their anticancer effect in multiple myeloma (MM) and T cells.51,52 Interestingly, only 
lenalidomide, amongst IMiDs, induces ubiquitination of Casein kinase 1a (CKIa), resulting in 
CKIa degradation. Indeed, lenalidomide induces the formation of two b-strands composed of 
CRBN residues 346-363.52 In turn, it might contribute to significant changes in the surface of 
CRBN near the IMiD binding site and thus it may determine differences in decreasing CK1a 
protein levels. 53  
Therefore, immunomodulatory drugs are a class of mono-functional molecules termed 
“molecular glues” which enhance PPIs between E3 ligases and neo-substrates for targeted 
degradation. Similar activity belongs also to the plant hormone auxin which binds to CRL1TIR1 
to induce depletion of Aux/IAA transcriptional repressor proteins.54  
More recently, the anticancer sulphonamides indisulam, E7820 and chloroquinoxaline 
sulphonamide (CQS) (namely SPlicing inhibitor suLphonAMides- SPLAMs) were also 
described as “molecular glues” (Figure 5).55,56 Indeed, these compounds were found to mediate 
interaction between DCAF15 and the pre-mRNA splicing factor RBM39 (or CAPERa), 
resulting in RBM39 ubiquitination and subsequently proteasomal degradation. However, X-
ray crystal structure of DCAF15-RBM39 complex will be necessary to prove the molecular 





Figure 5. Chemical structure of “molecular glues” targeting CRL4CRBN and CRL4DCAF15 
 
1.2 Proteolysis Targeting Chimeras (PROTACs) 
PROTACs are bifunctional molecules characterized by a linker connecting a ligand for a 
protein of interest (POI) and a second molecule able to recruit an E3 ligase (Figure 6). 
PROTACs, being able to bind simultaneously both proteins, lead to the formation of a ternary 
complex POI:PROTACs:E3 ligase. As result, the protein of interest is ubiquitinated and 





































Figure 6. Scheme of PROTAC approach (SRS: substrate recognition subunit) 
 
1.2.1 Peptide-based PROTACs 
The first PROTAC described in the literature, reported by Sakamoto et al.,9 aimed to induce 
degradation of methionine aminopeptidase-2 (MetAP-2). The heterobifunctional molecule 
consisted of the small molecule ovalicin, which binds to MetAP-2, attached via an 
aminohexanoic acid linker to a phosphor-decapeptide derived from IκBα inhibitor to recruit 
the E3 ubiquitin ligase SCFβ-TRCP. Ubiquitylation and degradation of MetAP-2 was demonstrated 
by adding the compound to Xenopus egg extracts using recombinant SCFβ-TRCP and substrate 
proteins. Shortly after, two parallel studies demonstrated the ability of PROTACs to promote 
degradation of target proteins in the cellular context.57 Estradiol-SCF and dihydrotestosterone 
(DHT)-SCF PROTACs were microinjected into Hek293 cells. These two PROTACs 
demonstrated the ability to target the estrogen receptor (ER) and androgen receptor (AR), 
deregulated in breast and prostate cancer, respectively.57 
The first cell-permeable PROTAC was developed by switching the IκBα-phosphopeptide 
component with a seven-amino-acid sequence (ALA-Hyp-YIP).58 The ALA-Hyp-YIP is a 
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HIF1α-derived motif recognized by VHL E3 ligase. Noteworthy, an eight-poly-D-arginine tag 
was added at the C-terminus of ALA-Hyp-YIP to improve cellular uptake. These compounds 
were used to induce degradation of FKBP12 protein, estrogen receptor, and the aryl 
hydrocarbon receptor upon the inclusion in the chemical structure of a cell-penetrating peptidic 
sequence.58 
Another interesting example is the discovery of PROTAC targeting the X-protein of the 
hepatitis B virus (HBV) consisting of the oxygen-dependent degradation domain of HIF1α 
fused to the X-protein oligomerization domain.59 Moreover, phospho-dependent proteolysis-
targeting chimeras (phosphoPROTACs) were developed to induce chemical knockdown of 
FRS2a and PI3K. PhosphoPROTACs comprised VHL binding peptide fragment, a receptor 
tyrosine kinase (RTK) phosphorylation sequence and a poly-D-Arg to enhance cell 
permeability. Upon RTK activation, the RTK sequence of PROTAC is phosphorylated and 
recruit downstream targets with phospho tyrosine-binding (PTB) and Src homology 2 (SH2) 
domains. Meanwhile, the VHL-binding sequence hijacks VHL E3 ligase to induce degradation 
of proteins of interest. Although their antitumor activity in mouse xenograft models, 
phosphoPROTACs were characterized by poor drug-like properties.60 
At this stage, PROTAC technology represented a mere proof-of-concept with potential as a 
chemical biology tool only. The highly peptidic- and phospho- nature of these early PROTAC 
compounds presented significant challenges and limitations associated with their metabolic 
instability, poor cell permeability and high molecular weight. For these reasons, the prospect 
of real applications in drug discovery remained far-fetched and the pharmaceutical industry did 
not take notice for many years.  
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1.2.2 Small molecule-based PROTACs 
The much needed improvements of stability, bio-distribution and permeability of PROTACs 
in cellular and potentially in vivo context motivated the development of more drug-like 
compounds. Transition from peptide-based PROTACs to small-molecule PROTACs was 
ushered by breakthrough development of small-molecule drug-like binders of E3 ligases (i.e. 
MDM2, cIAP1, CRBN and VHL).48,51 An early study in this direction involved the design of 
PROTACs targeting the androgen receptor (AR) by hijacking the p53-degrading Mouse 
Double Minute 2 (MDM2) E3 ubiquitin ligase. A non-steroidal androgen receptor ligand 
(SARM) was conjugated with the MDM2-TP53 inhibitor nutlin via a polyethylene glycol. A 
SARM-nutlin degrader was able to decrease AR protein level in cells, albeit only at high 
micromolar concentration (≥10 μM).61 In parallel, in another small molecule PROTAC 
approach, also termed SNIPER (Specific and Non-genetic IAPs-dependent Protein ERaser, 
IAPs = inhibitor of apoptosis proteins), Naito, Hashimoto and colleagues described degrader 
molecules that targeted the E3 ligase cIAP1 via the aminopeptidase inhibitor methyl ester 
bestatin.62 These early SNIPERs demonstrated depletion of cellular retinoic acid-binding 
protein (CRABP) I and II with all-trans retinoic acid ligands at micromolar concentration. 
Unfortunately, the bestatin methyl ester has off-target effects through inhibition of arginyl 
amino-peptidases and leukotriene A4 hydrolase, and, crucially, promoted concomitant cIAP1 
autoubiquitination and degradation – leading to loss of SNIPER-induced target degradation 
due to reduced cIAP1 activity. Nevertheless, subsequent SNIPERs were developed and shown 
to induce knockdown of other target proteins, including the retinoic acid receptor, the ER, the 
AR and acidic coiled-coil-3-containing protein.62–64 
Given the micromolar potency of these first small molecule PROTACs comparable to peptide- 
based PROTACs and the lack in selectivity, a strong incentive to design more potent and higher 




The availability of high quality VHL ligands prompted the development of VHL-based 
degraders.65–72 VHL ligand VH032 (Figure 4) has been incorporated into PROTACs reported to 
target the estrogen-related receptor (ERRα) and the serine/threonine kinase RIPK2. A 
thiazolidinedione-based ERRα ligand was linked to VH032 to yield a selective degrader enable 
to decrease ERRα protein levels in cells with a DC50 of 100 nM. Notably, in vivo experiments 
in mice demonstrates significant target knockdown in heart, kidney and xenografted tumors. 
For targeting RIPK2, VH032 was coupled to a RIPK2 inhibitor via a 12-atom linker (Figure 
7). PROTAC_RIPK2 shows DC50 of 1.4 nM and maximal degradation (Dmax) of 95% at 
concentration of 10 nM after 4 h treatment, a very fast effect given the protein’s half-life of 
approximately 60 h.66  
BRD4 targeted degradation was successfully achieved with VHL-recruiting PROTACs based 
on VH032 as VHL hijacking moiety.65,67 Bromodomain-containing protein 4 (BRD4) is an 
epigenetic protein, member of the bromodomain and external domain (BET) family, which 
plays a key role in the proliferation of cancer cells by regulating oncogene expression.73 Ciulli 
lab reported the first BRD4 degrader MZ1 in which the pan-BET inhibitor JQ1 is linked to 
VH032 by 3-unit polyethylene glycol linker (Figure 7). MZ1 demonstrated complete 
degradation of BRD4 after 3 h treatment and sustained up to 24 h. Interestingly, MZ1 and its 
analogues MZ2 and MZ3 showed preferential depletion of BRD4 over its homologs BRD2 and 
BRD3. Since MZ1 has comparable binding affinity between all BET homologs, this selective 
degradation beyond target engagement was an unexpected yet fascinating observation. This 
evidence suggests the potential of PROTACs to add a new layer of specificity to a promiscuous 
or non-completely selective binding ligand.65 A subsequent study reported a second series of 
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VHL-based BET degraders based on a more potent BET inhibitor I-BET726, which was 
derivatized via a distinct vector compared to JQ1.74 
The X-ray crystal structure of MZ1 bound with either VHL and BRD4 provided the first crystal 
structure of PROTACs reported in literature.68 This crystal structure shows that the MZ1 linker 
folds itself making possible novel and distinct PPIs between VHL and BRD4BD2 resulting in high 
stability and high cooperativity of the ternary complex. Based on these observations, rational 
design led to the discovery of AT1, a highly selective PROTAC active against BRD4 (Figure 
7).68 
ARV-771 represents another BRD4 degrader which links together JQ1 and VH032 (Figure 7). 
ARV-771 and MZ1 share the same target and E3 ligase, but they bear different linkers and a 
methyl modification on VHL ligand. This heterobifunctional compound induces depletion of 
all BET family proteins at concentration of 5-10 nM. Downstream effect was also observed at 
mRNA and protein level at concentration lower than 10 nM. Moreover, despite possessing Kd 
values similar to those of the JQ1-inhibitor, the PROTAC’s catalytic mechanism of ARV-771 
demonstrates a higher efficacy in reducing c-myc levels. Finally, ARV-771 activity in inducing 
tumor regression was confirmed in in vivo models of castration-resistant prostate cancer.67  
The bromodomain-containing co-regulator of transcription TRIM24 is another epigenetic 
target that has been successfully degraded by a PROTAC (Figure 7). dTRIM24 degrader 
induces rapid and sustained proteasomal degradation of TRIM24. In addition, dTRIM24 shows 
enhanced anti-proliferative effect compared to the inhibitor alone. Moreover, researchers have 
demonstrated, using dTRIM24 as chemical probe, the dependency of human acute leukemia 
cell on TRIM24 function.69  
Another example of a VHL-based PROTAC is compound 3i (Figure 7) designed to target a 
serine/threonine kinase, namely TANK-binding kinase 1 (TBK1), implicated in oncogenesis. 
Different linker lengths and compositions were explored. Compound 3i showed excellent 
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efficacy and selectivity, inducing a maximal degradation (Dmax) of 96% and showing a DC50 
value of 12 nM.70 
VHL-recruiting PROTACs were also developed as chemical dimerizers, to induce self-
ubiquitination and subsequent self-destruction of an E3 ligase, in an approach called Homo-
PROTACs. The most active homo-PROTAC compound CM11 (Figure 7) induced rapid, 
profound and selective degradation of VHL at 10 nM already after 4 h treatment. Moreover, 
VHL self-degradation with CM11 was found to be preferential for the long isoform of VHL, 
without significantly depleting the short VHL isoform. As a result, CM11 did not induce a 
HIF-dependent hypoxic response in cells. This work provided proof-of-concept that homo-
bifunctional molecules can be developed as a strategy to dimerize an E3 ubiquitin ligase and 
target it for degradation, allowing to probe its biology and relevance as therapeutic targets in 
ways not possible with E3 ligase inhibitors alone.71 Subsequently, homo-PROTACs for the E3 
ligase CRBN were also reported.75  
VHL-based PROTACs were also designed to target depletion of HaloTag fusion proteins, for 
example a green fluorescent protein (GFP)-HaloTag fusion.72 HaloTag is a modified bacterial 
dehalogenase that covalently binds to hexylchloride for functional protein analysis.76 
HaloPROTACs induced VHL- and proteasome-dependent degradation of GFP-HaloTag. The 
most potent HaloPROTAC induced more than 90% GFP-Halotag7 reduction and had a DC50 
value of 19 nM by 6 h. An exploration of linker length highlighted the key role of the linker in 












































































































































In the recent years, IMIDs have been identified as promising ligands for the development of 
PROTACs able to recruit CRBN E3 ligase.51 Two interesting studies were conducted to target 
degradation of BET proteins.77,78 In one study, compound ARV-825 was designed by coupling 
pan-BET inhibitor OTX015 to pomalidomide via a four-unit polyethylene glycol linker (Figure 
8). This PROTAC showed potent and rapid degradation of all BET homologs (BRD2, BRD3 
and BRD4) in Burkitt’s lymphoma cell lines. Moreover, ARV-825 exhibited sustained activity 
up to 24 h and downstream suppression of c-Myc levels, resulting in superior antiproliferative 
and apoptotic effects in comparison to BRD4 inhibitors JQ1 and OTX015.77 In a second study, 
BRD4 inhibitor JQ1 was coupled to a thalidomide derivative via a short alkyl linker, resulting 
in the dBET1 PROTAC (Figure 8). Consistent with the presence of the pan-BET inhibitor JQ1, 
quantitative proteomics analysis demonstrates chemical knockdown of all BET family and of 
c-Myc levels in acute myeloid lymphoma (AML) cells. Furthermore, dBET1 activity has been 
investigated in xenograft mouse model of AML cells, showing tumor regression in a 14-day 
treatment.78  
Lai and co-workers described degraders to mediate elimination of the protein kinase c-ABL 
and its oncogenic fusion protein BCR-ABL. To target c-ABL and BRC-ABL, three tyrosine 
kinase inhibitors (TKIs, namely imatinib, bosutinib and dasatinib) were employed. 
Recruitment of CRBN and VHL E3 ligases was directly compared for the same kinase ligands 
and distinct linker variations. In K562 leukemia cell line, imatinib-based degraders did not 
induce degradation of the proteins of interest. c-ABL and BCR-ABL proteins were degraded 
using PROTAC bearing bosutinib linked to pomalidomide, but no activity was detected for 
VHL ligand-containing compounds. The activity of dasatinib-CRBN degrader (DAS-6-2-2-6-
CRBN, Figure 8) was similar to that of the bosutinib-pomalidomide pair, while the 
corresponding VHL-based PROTAC degraded only c-Abl. Of note, all PROTACs were shown 
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to bind and inhibit BCR-ABL and c-ABL in cells, irrespective of their degradation activity.79 
This work, together with the study on BRD4 degraders, confirmed that degradation involved 
more than just target binding, underlining the important influence of the target warheads, the 
recruited E3 ligase and the linkers on PROTAC functionality.65,68,77–79 
CRBN-based PROTAC degraders were developed to knockdown the bromodomain-containing 
protein 9 (BRD9), emerged as an attractive therapeutic target in cancer. Compound dBRD9 
(Figure 8), induces rapid, potent and selective degradation of BRD9 and is endowed with anti-
proliferative effect against human acute myeloid leukemia cell lines.80  
Others examples of CRBN-recruits PROTACs aim to target SIRT2,81 CDK9,82 PCAF/GNC583 




Figure 8. Chemical structures of CRBN-recruiting PROTACs 
 
1.3 Advantages of PROTAC system over inhibition 
PROTACs offer a range of unique advantages relative to traditional small-molecule inhibitors. 
Conventional small-molecule inhibition is based on occupancy of the binding site of target 
protein. Thus, occupancy-driven strategy requires high concentration of high-affinity drug to 
achieve and maintain a high level (typically over 90%) of target engagement. In turns, the high 
dose could limit the duration of a functional response, with the risk of severe off-target or 
unwanted side effects, leading to toxicity in therapeutic settings. Instead, PROTACs mediate a 
















































































Indeed, PROTACs act as agonists to catalytically initiate a degradation cascade: after a first 
round of target ubiquitination and degradation, the degrading machinery and the compound 
will be available to start a new catalytic cycle. A consequence of the catalytic mode of action 
is that degraders can function at sub-stoichiometric receptor occupancies. It means that desired 
protein degradation can be observed at concentrations much lower than degrader binding 
dissociation constants (Kd) from the target, reducing the requirement for full target 
engagement.84,85 The required PROTAC concentrations are also lower than those needed to 
achieve E3 ligase inhibition.85 For example, PROTAC_RIPK266 binds to VHL E3 ligase with Kd 
of 0.5 μM, while induced degradation of RIPK2 results in half-degrading concentration (DC50) 
of 1 nM. Moreover, to achieve sufficient VHL inhibition, the required PROTAC_RIPK2 
concentrations are less than 10 μM leading to a significant window between desired 
degradation-induced pharmacology and unwanted inhibition-induced effects. A further 
consequence of the catalytic mechanism is an often time-dependent degradation with greater 
protein depletion seen over time.85 
Targeted protein degradation with PROTACs offers a strategy to modulate the functional 
selectivity of a ligand, thus providing highly selective degraders with reduced side effects. High 
selective degradation is often achieved incorporating a highly selective ligand into a degrader. 
However, appropriate designed PROTACs could add a layer of target selectivity compared to 
the intrinsic binding selectivity of the ligand.65,68,74,86 Selective stabilization of the ternary complex 
and subsequent selective degradation could be achieved by rational PROTAC design thanks to 
the availability of crystal structures.68,87 
The mounting interest in degraders is also motivated by the possibility to target proteins that 
lack of suitable binding site, including transcription factors, scaffolding proteins, non-
enzymatic proteins, deemed “undruggable” via conventional occupancy-based strategy.16 In 
contrast to degraders that act independently from the functional site, inhibitors need to interact 
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with well-defined pockets to affect protein function which might be insufficient to block 
protein activity and it could lead to feedback response. Thereby, post-translational protein 
degradation determines removal of entire protein. This effect is different than simply blocking 
a binding site and it closely phenocopies genetic knockdown/knockout strategies, leading to 
significantly improved pharmacology (i.e. more sustained cellular effect and extended duration 
of action).85 Once the protein of interest has been degraded, PROTACs are available to deplete 
the smaller pool of de novo re-synthesized protein. Since the slow turnover rate of many 
proteins, efficient protein knockdown might be maintained with the still available modest 
concentration of degraders or even after clearance for a significant period of time. This 
characteristic, together with the catalytic mode of action, allow for low drug exposures (Cmax 
and AUC), low dose and long dosing interval, resulting in suitable subcutaneous or 
intramuscular administration routes in addition to intravenous administration.85 
Finally, PROTACs can be broadly applicable in light of the conservation and essentiality of 
the UPS and the fact that E3 ubiquitin ligases such as CRBN and VHL are widely expressed 
across different cells. 
 
1.4 Challenges of PROTAC development 
The PROTAC strategy has been continuously and significantly improved in the last 15 years, 
yet many questions remain to be addressed that could greatly inform and drive future 
therapeutic applications.  
A general methodology for an efficient PROTAC design would be desirable. Important 
parameters to keep in consideration during their design are chemical stability, solubility and 
permeability. Key points of the design are also the choice of the E3 ligase, the selection of 
target ligands and their conjugation pattern. The properties of the linkers, such as length, 
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composition and site of attachment are known to be important and to impact on activity varying 
in a context- and target-dependent manner.70,71,74,88,89  
Another challenge is the development of ligands binding the target proteins and the E3 ligase; 
despite the large number of E3 proteins (> 600), only few good-quality ligands have been 
discovered and successfully used for PROTACs, and CRBN and VHL are to date the only 
ligases most widely used for PROTACs.21 
The first barrier to face in PROTAC development is their cellular uptake: the designed degrader 
must access the appropriate intracellular compartment to bring target protein and UPS in close 
proximity. The larger size compared to small molecule inhibitors may result in a slower rate of 
membrane crossing. However, despite their molecular weight (typically in the 700-1100 Da 
range) and polar surface area values, the examples reported in literature so far have shown that 
the concentration of degraders achieved inside the cell is clearly adequate to drive highly potent 
effect.  
Once inside the cells, the molecule should enable the formation of the ternary complex bringing 
target protein and E3 ligase in close proximity. Thermodynamic and kinetic properties of the 
ternary complex should be considered during PROTAC development.68,87 In contrast to the 
binary system, thermodynamics of the ternary complex has been described by bell-shaped dose 
responses so-called “hook-effect”.90 This effect leads to less efficient ternary complex formation 
at high concentrations, favouring the saturation of the two proteins with the degrader.  
The interaction between degrader and one protein might favour ternary complex formation 
leading to positive cooperativity (that is a thermodynamic parameter that can be used to 
describe favourable or repulsive interactions between two proteins) or disfavour it by steric 
clashes (negative cooperativity). 
Appropriate conformation of the ternary complex is also necessary to allow ubiquitination of 
target protein.91 Another limiting step might be the activity of deubiquitinase enzymes (DUBs) 
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which catalyse the removal of ubiquitin from proteins. Indeed, ubiquitination of target proteins 
should proceed at correct rate to overcome any competing ubiquitin removal by DUBs.92 Also 
the ubiquitination patter should facilitate efficient proteasomal recognition and avoid other 
cellular responses due to different polyubiquitin linkages and chain length.15 
PROTAC-induced protein degradation has yielded impressive preliminary efficacy in a limited 
number of cellular and in vivo systems, leading to numerous high quality chemical probes and 
lead compounds with significant therapeutic potential. The first PROTAC compounds are 
expected to enter clinical trials in early 2019, and these first clinical studies will be important 
to assess the real potential of PROTACs as new medicines. 
 
1.5 Aims and objectives  
The broad research theme of this PhD program is the design, synthesis and evaluation of the 
biological activity of PROteolysis TArgeting Chimeras (PROTACs), a fascinating novel 
approach for drug discovery to induce the degradation of a target protein using small 
molecules.  
The aim of my PhD project is to design PROTACs against different target proteins to further 
contribute to pharmaceutical research in the field of targeted protein degradation. My PhD 
work has been divided into two parts. One part of my research activity was carried out at the 
University of Dundee, under the supervision of Professor Alessio Ciulli. This part of my thesis 
involved the design, synthesis and biological evaluation of PROTACs targeting the 
bromodomain-containing protein 7 and 9 (BRD7 and BRD9). 
The second part of my work was carried out at the Department of Chemical Core Technologies, 
within Nerviano Medical Sciences (Milan), supervised by Doctor Eduard Felder. With the 
future prospect of extending the development of PROTACs to other targets, it was planned to 
study a literature example, in order to confirm the proof of concept. Among the available 
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molecules, it was chosen a degrader targeting the tyrosine kinase c-ABL and its oncogenic 
fusion protein BCR-ABL. Then, the development of PROTACs was extended to other protein 



































2. BRD7 and BRD9 targeting PROTACs 
 
2.1 Introduction  
2.1.1 Bromodomains 
In eukaryotic cells, post-translational modification (PTMs) are stable chemical modifications 
of histone proteins around which DNA is wrapped.93 PTMs are essential to regulate gene 
expression because they influence the access of transcription machinery to the chromatin 
compact organisation of the genetic material. N-acetylation of lysine residues on histones and 
other proteins is the most abundant and studied PTM process associated with chromatin 
architecture and transcriptional activation.94–96 In order to recruit the transcription machinery, the 
degree of compactness of the chromatin is regulated by acetyltransferases (HATs) and histone 
deacetylases (HDACs), “writers” and “erasers” of acetyl marks, respectively.  
Another class of epigenetic proteins is represented by bromodomain-containing proteins 
(BRDs), “readers” of acetyl-lysine (KAc) residues.94 The human genome encodes for 61 
bromodomains which are present in 46 diverse nuclear and cytoplasmic proteins divided in 8 
subfamilies, based on structure and sequence similarity.96,97 Despite the large sequence 
variations, bromodomains are structurally conserved modules that comprise four a-helices 
(known as aZ, aA, aB and aC), linked by two flexible loop regions (known as ZA and BC 
loops), to form the KAc binding site.97 Structural data have showed two hydrogen bonds 
responsible for acetyl-lysine residue recognition: one between the carbonyl moiety of KAc and 
the N-terminus of an asparagine residue, and another interaction with the hydroxy group of a 
Tyr residue via a conserved water molecule present in the binding site.98  
The hydrophobicity of cavity makes the bromodomain attractive target for inhibition of 
protein-protein interaction.96 Indeed, BRDs such as transcriptor co-regulators (BET protein 
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BRD4 and ATAD2), E3 ubiquitin ligases (TRIM24), transcriptional repressors (BAZ2A) and 
chromatin-remodeling factors (CECR2) represent valuable pharmacological targets for the 
treatment of different diseases. 
In particular, the Bromo- and Extra-terminal (BET) subfamily comprises four members in 
humans (namely, BRD2, BRD3, BRD4 and BRDT) bearing two related bromodomains 
(namely, BD1 and BD2) which recognize different KAc residues in H3 and H4 histone tails.99 
Potent chemical probes for BET subfamily registered in clinical trials (i.e. RVX-208,100 I-
BET762,101 OTX015102 and (+)-JQ1103 among others) have shown profound anticancer and anti-
inflammatory properties. 
More recently, there has been also intense interest in non-BET bromodomains proteins to 
unravel their biological function and to explore their role in cancer and other human 
diseases.80,104–108 Prominent examples are bromodomains of bromodomain-containing protein 9 
(BRD9) and its analogue bromodomain-containing protein 7 (BRD7), components of the 
SWI/SNF chromatin remodelling complexes.109,110 
 
2.1.2 BRD7 and BRD9 proteins 
BRD7 and BRD9 belong to the forth subfamily of bromodomains sharing 85% of sequence 
identity between them.104 These homolog domains have been identified as subunits of BAF 
(BRG-/BRM-associated factor) and PBAF (Polybromo-associated BAF) complexes, 
respectively.109,110 BAF and PBAF represent two variants of the SWI/SNF complex, one of the 
four mammalian ATP-dependent chromatin remodelling complexes, which plays a key role in 
gene regulation, DNA replication and DNA repair.111 SWI/SNF complex modulates access to 
promoters and coding regions of DNA through modification of the degree of compactness of 
chromatin. This activity is crucial to the productive recruitment of transcription machineries 
and therefore controls and regulates gene expression.112,113 The first relationship between 
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SWI/SNF complexes and cancer emerged in the 1990s, as several genes coding for SWI/SNF 
subunits were identified as tumour suppressors.114,115 For example, loss of the SMARCB1 subunit 
was identified in malignant rhabdoid tumour (MRT), while loss of BRG1 (brahma-related gene 
1) and BRM (brahma), encoded by the SMARCA4 and SMARCA2 genes, respectively, was 
linked to breast cancer.116,117 However, only recently, deep genome-sequencing has revealed that 
mutations of BAF/PBAF constitutive subunits are found in 20% of human cancers.109  
Emerging evidence indicates that BRD7 and BRD9 have key roles in tumorigenesis and, 
consequently, these proteins are potential drug targets. BRD9 is mainly overexpressed in 
several malignancies, such as cervical cancer and in non-small cell lung cancer (NSCLC).118,119 
Instead, BRD7 has been proposed as candidate tumour suppressor gene, being frequently 
down-regulated in malignancies, such as breast cancer, NPC, ovarian cancer, gastric cancer, 
colorectal carcinoma and prostate cancer.120–123 In particular, it has been disclosed that BRD7 
gene regulates breast cancer cell metabolism,124 being a negative regulator of aerobic glycolysis 
essential for tumour progression.125 In contrast, it has recently been suggested that BRD7 
knockdown could be an attractive target for cancer immunotherapy, showing that inactivation 
of BRD7 sensitizes tumour cells to T cell-mediated killing.126  
To explore the therapeutic potential of BRD7/9, structure-guided medicinal chemistry 
campaigns were carried out to identify potent and selective chemical probes. Compounds I-
BRD9104, LP99105, ketone “compound 28”106, BI-7273 and BI-9564107, and GNE-375108 (Figure 9) 
have been used in cells to help clarifying the roles of BRD7/9 in oncology and other disease. 
For example, pharmacological studies of inhibitors BI-7273 and BI-9564 in combination with 
domain-swap protein engineering revealed BRD9-dependency on sustaining MYC 
transcription and maintaining the leukemic cellular state in hematopoietic cancer via its 
bromodomain.107,127 In a separate study, the effect of LP99 on the expression of pro-inflammatory 
cytokines suggests BRD7/9 bromodomains as potential targets for anti-inflammatory 
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treatment.105 In yet another study, blockade of BRD9 bromodomain with I-BRD9 identified its 
role in the regulation of several cancer related genes.104 These investigations provide a rationale 
for targeting non-BET protein for treatment of diseases. 
 
 
Figure 9. Chemical structures of BRD7 and BRD9 bromodomain inhibitors. 
 
2.1.3 Aims and objective 
Although inhibitors are useful tools to explore the therapeutic potential of bromodomain target 
proteins, significant challenges and limitations of single domain blockade are relevant for 
multi-domain proteins. In the context of multiprotein complexes, inhibition of a single domain 
might not be completely essential to target activity which may for example depend on the 

































as disclosed by Hohmann et al.,127 BRD9 inhibition determines partial release of the SWI/SNF 
complex from the chromatin, disrupting only a single interaction with lysine acetylated (KAc) 
motifs on histone proteins. Moreover, occupancy-driven target inhibition often fails to 
phenocopy the genetics expected by traditional genetic knock-out/knock-down due to the 
mechanistically difference between blockade and removal of the protein.128 These limitations 
could all be circumvented by inducing pharmacologically protein degradation with a PROTAC.  
On the basis of these observations, my PhD project was focused on the feasibility of targeting 
BRD7/9 for degradation and on the identification of a suitable target-ligase pair. In this regards, 
during the course of this research, Remillard and colleagues80 described the design and the 
characterization of dBRD9, a selective chemical BRD9 degrader recruiting CRBN E3 ligase. 
Moreover, in the same work, BRD9-VHL PROTAC combinations were shown to be inactive.  
Undeterred by these findings and encouraged by our initially results, a structure-activity 
relationship (SARs) study was carried out to explore the impact of target ligands, linkers 
composition and conjugation patterners on BRD7/9 degradation.  
 
Therefore, the goal of my PhD project is to design, synthesise and characterize PROTACs 










2.2 Design, synthesis and biological evaluation of first-generation degraders 
In next paragraphs, the design, synthesis and biological evaluation of fist-generation 
compounds targeting BRD7 and BRD9 proteins will be described.  
 
2.2.1 Design of first-generation compounds 
A first set of PROTACs able to induce BRD7/9 degradation by recruiting three different E3 
ubiquitin ligases (namely, VHL, CRBN and DCAF15) was designed. The choice of target and 
E3 ligase ligands was motivated by the availability of high-quality small ligands, allowing us 
to increase diversity and maximizing the opportunity for complementary surfaces between the 
bromodomain and the ligase within ternary complexes. By this first series of compounds, the 
impact of linker length, composition and derivatization vectors on activity was evaluated. 
 
2.2.1.1 BRD7/9 ligand: BI-7273107 
Derivative BI-7273107 (Figure 9) was selected as BRD7/9 bromodomain ligand because of its 
high binding affinity and its demonstrated superiority as BRD9 chemical probes over other 
ligands. The key feature of this compound is the 2-methyl-2,7-naphthyridin-1-one scaffold that 
improved selectivity for BRD9 over the BET protein family by inducing a change in the torsion 
angle between the anchor binder and the ZA channel linker rings and by improving p-stacking 
interaction with Tyr106 in BRD9 anchor region (Figure 10). Moreover, the electron-donating 
groups on the phenyl group enhanced potency by improving T-stacking interaction with Phe44 




Figure 10. Crystal structure of BI-7273 (magenta) bound to BRD9 (PDB: 5EU1) 
[Ref.107]. Residues Tyr106 and Phe44 are shown as sticks. 
 
To design the first-generation of degraders, we inspected the crystal structure of BI-7273 bound 
to BRD9 (PDB code: 5EU1)107 to identify solvent exposed attachment points and vectors for 
linker conjugation, which are known to greatly influence PROTAC degradation profiles.71,74 The 
dimethylamine terminal group of the molecule was identified as a suitable group not being 
involved in any key interactions with the protein (Figure 10). For derivatization purposes, the 
dimethylamine group of compound BI-7273 was replaced by a piperazine group (BrdL1), 
providing a synthetically convenient and isosteric handle (Figure 11).  
 
 
Figure 11. Chemical structures of parent (BI-7273) and modified (BrdL1) BRD7/9 ligand. 
















2.2.1.2 Degraders recruiting CRL2VHL 
The high-affinity VHL binders VH032 (Kd = 185 nM), VH298 (Kd = 90 nM) and VH101 (Kd = 
44 nM)43,48,129 were selected as VHL E3 ligase recruiting moieties (Figure 12). The SAR studies 
on VH032 led to compounds VH298 and VH101 with increased binding affinity and cell 
permeability. The terminal acetyl group of VH032 was replaced with either a cyanocyclopropyl 
group (VH298, PDB 5LLI) or with fluorocyclopropyl group (VH101, PDB 5NVX). In order 
to maintain the strong binding affinity of these compounds, the already available co-crystal 
structures43,48,129 were analysed to identify the portion suitable for the derivatization of the ligands 
without perturbing their binding modes. From previous studies, it was reported that the 
hydroxyproline (Hyp) scaffold forms hydrogen bonds with His115 and Ser111 side chains of 
VHL.36,130 Moreover, the methylthiazole ring binds to right-hand side (RHS) pocket of VHL in 
an energetically stable conformation.48 It was also known that the tert-butyl group points 
upward resulting in hydrophobic contacts with Phe91 and Trp88 side chains.48 Therefore, it was 
assumed that the Hyp, the thiazole ring and the tert-butyl group were not available for 
modification. However, the methyl group of VH032 terminal acetyl group was found eligible 
for linker conjugation and was modified to afford compound VHL1 without perturbing the key 
interaction within the VHL binding site, as previously demonstrated (Figure 12).65,66,77,79 
Furthermore, we explored a conjugation vector via phenolic position 2 on the phenyl ring of 
VH032 (VHL2, Figure 12), already reported as suitable linker-conjugation region.71,72 
Concerning VH298 and VH101, they were only derivatized at the position 2 of the phenyl ring 
(VHL3 and VHL4, respectively; Figure 12), in order to leave undisturbed the key cyano- and 




Figure 12. Chemical structures of parent (VH032, VH298 and VH101) and modified 
(VHL1-4) VHL ligands. Functional groups selected for conjugation are shown in blue on 
parent ligand and in red on modified ligand. 
 
In addition to the site of attachment, the chemical and physical properties of linkers (e.g. length 
and composition) are known to impact on compound activity in a target- and context-dependent 
fashion.70,71,74,88,89 Widely used linkers are polyethylene glycol (PEG) chains. Their flexibility 
facilitates the formation of the ternary complex bringing the E3 ligase productively in close 
proximity to the target protein for ubiquitination and subsequent degradation.  
We designed PROTACs recruiting CRL2VHL using PEG linkers composed of two, three, four 
and five ethylene glycol units and a more lipophilic 11-atoms chain was inserted (Table 1). 
Moreover, a different attachment to BrdL1 moiety via amide conjugation instead of amine was 
































































Table 1. Structural features of first-generation of VHL-based BRD7/9 PROTACs 
 
 
Structural features of first-generation of VHL-based BRD7/9 PROTACs 
Code BrdL Linker E3 ligase ligand 
Linker length 
(atoms) 












17  5 
VZ55 
 
11  2 
DAT152a 
 
11  3 
DAT157a 
 
11  3 
VZ117 
 
VHL2 8  2 
VZ96 VHL3 8 2 
VZ95 VHL4 8 2 
VZ118 
 
VHL2 14 4 
VZ97 VHL3 14  4 
VZ98 VHL4 14 4 
a Provided by Dr Andrea Testa, University of Dundee. 
 
2.2.1.3 Degraders recruiting CRL4CRBN 
To explore the possibility of inducing degradation of BRD7/9 proteins with the formation of 
different ternary complex, a small set of PROTACs recruiting CRL4CRBN was designed (Table 



























In recent years, thalidomide (after being banned for its teratogenic properties) and its 
derivatives pomalidomide and lenalidomide have gained interest as immunomodulatory drug 
and antineoplastic (IMIDs). In particular, lenalidomide (marketed as Revlimid® by Celgene) 
is extensively used as front-line drug for the treatment of multiple myeloma and was the top 
selling cancer drug in 2016.50 As reported in the literature, IMIDs act as agonist and antagonist 
on CRBN.51 In fact, IMIDs on one hand prevent the binding to CRBN of endogenous substrates 
such as MEIS2 and, on the other hand, are able to induce the recruitment of the non-
physiological substrates Ikaros and Aialos (two transcription factors overexpressed in multiple 
myeloma) promoting their proteasomal degradation (see section 1.1.4).51  
Pomalidomide was selected as CRBN ligand because of its great cellular stability. Its crystal 
structure in complex with CRBN (PDB code: 4CI3)51 suggested that the amine at position 4 of 
the phthalimide ring could provide a suitable connecting point for the linkers (Figure 13). 
 
 
Figure 13. Crystal structure of pomalidomide (cyan) bound to CRBN (PDB code: 4CI3).  
 
Due to the poor reactivity of the aromatic amine group, pomalidomide was converted into 
POMA compound (Figure 14), characterized by an amine functionality suitable for the 




Figure 14. Chemical structures of pomalidomide and its analogue POMA. Functional 
groups selected for conjugation are shown in blue on parent ligand and in red on modified 
ligand. 
 
Table 2. Structural features of first-generation of CRBN-based BRD7/9 PROTACs 
 
 
Structural features of first-generation of CRBN-based BRD7/9 PROTACs 
Code BrdL Linker E3 ligase ligand 
Linker length 
(atoms) 
# of O 
atoms 
VZ109 




14  4 
 
2.2.1.4 PROTACs recruiting CRL4DCAF15 
To further extend the study, we designed BRD7/9 degraders recruiting the E3 ligase CRL4DCAF15 
(compounds VZ89 and VZ90, Table 3). Indisulam55,56 was selected as the ligand for CRL4DCAF15. 
This aryl sulphonamide seems to redirect the activity of the CRL4DCAF15 complex towards the neo-
substrate CAPERα (also known as RBM39, section 1.1.4).55,56 As the binding mode of Indisulam 
is not known, we leveraged information on the activity of a biotinylated photoactive analogue 
probe to guide our conjugation strategy.55 Accordingly, a para-benzylamine derivative of 

































PEG linkers composed of two or four ethylene glycol units were used to connect the two 
warheads, BrdL1 and Indisulam derivative (Table 3). 
 
 
Figure 15. Chemical structures of DCAF15 ligand Indisulam its benzylamine analogue. 
Functional groups selected for conjugation are shown in blue on parent ligand and in red on 
modified ligand. 
 
Table 3. Structural features of first-generation of DCAF15-based BRD7/9 PROTACs 
 
 
Structural features of first-generation of DCAF15-based BRD7/9 PROTACs 
Code BrdL Linker E3 ligase ligand 
Linker length 
(atoms) 
# of O 
atoms 
VZ89 







































2.2.2 Synthetic routes of first-generation compounds 
In this chapter, the synthetic routes to obtain BRD7/9-targeting degraders of the first generation 
are described. First, it is reported the synthetic procedures applied to obtain the BRD7/9 and 
the E3 ligase ligands. Then, the synthesis of the linkers and the assembly of the final 
compounds are described. 
 
2.2.2.1 Synthesis of BRD7/9 ligand: BrdL1 
BrdL1 synthesis has been carried out by a convergent approach as detailed in Scheme 1. Thus, 
the reaction of 4-methyl-3-cyanopyridine 1 (commercially available) with DMF acetal in 
refluxing DMF followed by treatment with glacial AcOH/H2SO4 led to the formation of 2,7-
naphthyridin-1-one (2) in 74% yield. Iodination of 2 with I2/NaOH afforded 3 which was then 
methylated to yield the key building block 4. The higher electronegativity of the 1-oxopyridine 
ring over the unsubstituted pyridine ring determined the high regioselectivity of iodination. 
Next, Miyaura-Suzuki cross-coupling (one-pot two-step) was conducted between the organic 
halide 4 and tert-butyl 4-(4-bromo-2,6-dimethoxybenzyl)piperazine-1-carboxylate (6), 
previously obtained by reductive amination between 4-bromo-2,6-dimethoxybenzaldhehyde 5 
and boc-piperazine in 97% yield. The Miyaura reaction involved the generation of a mixture 
of boronate and boronic acid of compounds 6, while in the second step (Suzuki coupling) 4 
and a 2M degassed aqueous solution of K2CO3 were added. Microwave heating improved the 
yield and reduced the reaction time. After cleavage of the tert-butyloxycarbonyl protecting 






Scheme 1. Synthesis of BRD7/9 ligand BrdL1 
 
Reagents and conditions: (a) DMF acetal in refluxing DMF, 160 ºC, overnight; then, 
CH3COOH, H2SO4, 130 ºC, 2 h, yield 74%; (b) I2, NaOH 0.4N, 80 ºC, 5 h, yield 53%; (c) NaH, 
CH3I, DMF, 0 ºC, 5 h, yield 95%; (d) 1-Boc-piperazine, NaBH(OAc)3, THF, rt, overnight, yield 
97%; (e) step 1: 6, B2pin2, KOAc, Pd(dppf)Cl2, 1,4 dioxane, µw 140 ºC, 40 min; step 2: 4, K2CO3 
(aq) are added to step 1, µw 120 ºC, 30 min, yield 55%; (f) HCl 4M in dioxane, DCM, rt, 1 h, 
quantitative yield 
 
2.2.2.2 Synthesis of VHL2-4 
The synthesis of VHL ligands (VHL2-4)43,48,71,72,129 characterized by the hydroxyl group at position 
2 on the phenyl ring is reported in Scheme 2. The reduction of 2-hydroxy-4-(4-methylthiazol-
5-yl)benzonitrile 8 (synthetized as previously reported48) led to benzylamine compound 9 that 
was coupled with Boc-L-hydroxyproline to afford compound 10. After BOC deprotection, 11 
was reacted with Boc-L-tert-leucine in the presence of HATU, and the key intermediate 12 
was isolated after removal of BOC protecting group. Acetylation of compound 12 using acetyl 
imidazole led to the formation of VHL2 (13) in 51% yields. Alternatively, 12 was coupled with 
1-cyano and 1-fluoro-cyclopropanecarboxylic acid in the presence of DIPEA, to afford 










































Scheme 2. Synthesis of VHL2-4 
 
Reagents and conditions: (a) LAH, THF, 55 ºC, overnight, yield 41%; (b) Boc-L-
hydroxyproline, HATU, HOAt, DIPEA, DMF, rt, 1 h, yield 78%; (c) 4M HCl in dioxane, 
quant. yield; (d) Boc-L-tert-leucine, HATU, HOAt, DIPEA, DMF, rt, 1 h, yield 94%; (e) 4M 
HCl in dioxane, quant. yield; (f) 1-acetylimidazole, DIPEA, DMF, rt, 3 h, yield 51%; (g) acid 
derivatives, HATU, HOAt, DIPEA, DMF, rt, 1 h, yield 50-56% 
 
2.2.2.3 Synthesis of Indisulam derivative 
For the synthesis of indisulam analogue 21 we applied minor changes to a procedure already 
published by Owa et al.131 (Scheme 3). Briefly, the chlorination at position 3 of 7-nitroindole 16 
using N-chlorosuccinimide led to 3-chloro-7-nitroindole 17 (94 % yield) which was reduced, 
in quantitative yields, in a sealed vial with Fe/NH4Cl. Next, 18 was coupled with 4-
formylbenzenesulfonyl chloride 19 in pyridine to afford 20 in good yield. The last reductive 
amination was a tricky reaction, due to the higher reactivity of the primary amine over the 
aldehyde. First of all, we tried to generate in situ the imine by using NH4OAc and NaCNBH3 in 
a EtOH:THF mixture. However, the imine was unstable and it self-condensed giving the 
undesired compound shown in Figure 16. To overcome this problem, a different approach was 





















































































in ethanol led to the corresponding oxime that was too stable and it did not reduce to amine, 
even if more zinc was added and heating was applied. In the final and successful attempt, 
reductive amination was carried out using an excess of ammonia in order to push the reaction 
and to avoid self-condensation. Thus, reaction between compound 20, a saturated solution of 
NH4OAc in ethanol, NaCNBH3 and 30% ammonia afforded indisulam derivative (21) in 35% 
yield after HPLC purification using a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous 
solution of formic acid. 
 
Scheme 3. Synthesis of Indisulam derivative (21) 
 
Reagents and conditions: (a) NCS, 0.1N HClaq, THF, rt, 5 h, yield 94%; (b) Fe, NH4Claq, 2-
propanol, 80 ºC, overnight, yield quant.; (c) 4-formylbenzenesulfonyl chloride, Pyr, EtOAc, rt, 
3 h, yield 62%; (d) NH4OAcsat in EtOH, NaBCNH3, 30% NH3, 100 ºC, 15 min, yield 35% 
 
 
Figure 16. Undesired compound: N-(3-chloro-1H-indol-7-yl)-4-(((4-(N-(3-chloro-1H-
indol-7-yl)sulfamoyl)benzyl)amino)methyl)benzenesulfonamide 
 
2.2.2.4 Synthesis of PROTACs recruiting CRL2VHL 
The synthesis of bivalent molecules bearing VHL1 (synthesized as previously reported48) and 




















































polyethylene glycols were mono-protected using benzyl bromide to obtain the corresponding 
monobenzyl ethers 24 and 25 in good yields. Next, biphasic reaction of compounds 24 and 25 
and tert-butyl bromoacetic acid in presence of 37% aqueous solution of NaOH, using tetrabutyl 
ammonium bromide (TBAB) as a phase-transfer catalyst in stoichiometric amount, led to 
compounds 26 and 27. The linkers were then deprotected via H-cube hydrogenation affording 
compounds 28 and 29 in excellent yield. Compound 30 was already available in the lab, 
prepared as described for linkers 28 and 29 starting from PEG5. 
The primary alcohol functionality of the linkers 28-30 was oxidized to aldehyde group under 
the Swern reaction conditions and condensed with BrdL1 to afford the desired compounds 31-
33. Further deprotection of the tert-butyloxy protecting group in acidic conditions led to 
intermediates 34-36 in quantitative yield. The HATU-mediated coupling of intermediates 34-
36 with VHL1 led to the final compounds VZ48, VZ49 and VZ52 which were purified by 
preparative HPLC. 
 





24 n=2  80%








28 n=2  93%












































31 n=2  32%
32 n=4  34%








































 VZ48 n=2 44%
 VZ52 n=4 30%










Reagents and conditions: (a) NaH, BnBr, DMF, rt, overnight; (b) tert-butyl-bromoacetate, 
TBAB, 37% NaOH/H2O, DCM, rt, overnight; (c) EtOH, 65 ºC, 1 atm, 1 mL/min; (d) (COCl)2, 
TEA, DMSO, DCM, -78 ºC to rt, 2 h; (e) NaBH(OAc)3, TEA, DCE, rt, overnight; (f) TFA, 
DCM, rt, 2 h; (g) VHL1, HATU, HOAt, DIPEA, DMF, rt, 2 h 
 
The VHL-based PROTAC VZ55 characterized by a 11-atoms length lipophilic linker 
containing two oxygen atoms was prepared according to the synthetic route reported in Scheme 
5. In details, the nucleophilic attack of diethylene glycol 37, deprotonated with sodium hydride, 
to 6-bromo-1-hexene led to compound 38 in good yield. Oxidation of the free hydroxyl group 
using BAIB and TEMPO afforded the carboxylic acid 39 which was then condensed with 
VHL1 and compound 40 was isolated. Intermediate 40 was then oxidized under the Lemieux-
Johnson conditions to the corresponding aldehyde. This reaction involved the in situ formation 
of the diol using osmium tetroxide and its subsequent cleavage by sodium periodate. The 
resulting aldehyde derivative was directly used for reductive amination reaction with BrdL1, 
affording compound VZ55 that was purified by preparative HPLC. 
 
Scheme 5. Synthesis of compound VZ55 
 
Reagents and conditions: (a) NaH, 6-bromo-1-hexene, DMF/THF, rt, overnight; (b) BAIB, 
TEMPO, ACN/H2O, rt, overnight; (c) VHL1, HATU, HOAt, DIPEA, DMF, rt, 2 h; (d) OsO4 4 
wt.% in H2O, NaIO4, pyridine, dioxane/ H2O, rt; (e) BrdL1, NaBH(OAc)3, TEA, DMF, rt, 
overnight 
 
A similar approach was applied for the synthesis of PROTACs VZ95-98 and VZ117-118 

















































ring of the VHL ligand (Scheme 6). Briefly, the nucleophilic substitution of 41 and 42 with 
allyl bromide led to compounds 43 and 44 that were activated as mesylates and condensed with 
VHL2-4 to afford intermediates 45 and 50. The alkene moieties of 45 and 50 were then 
oxidized to aldehyde under the Lemieux-Johnson conditions and directly reacted with BrdL1 
by reductive amination to obtain the final products VZ95-98 and VZ117-118. All the final 
compounds were purified by preparative HPLC to obtain compounds of high purity required 
for biological evaluation. 
 
Scheme 6. Synthesis of compounds VZ95-98 and VZ117-118 
 
Reagents and conditions: (a) NaOH, allyl bromide, dioxane, rt, overnight; (b) MsCl, TEA, 
DCM, rt, 3 h; (c) VHL ligands VHL2-4, K2CO3, DMF, 70 ºC, overnight; (d) OsO4, NaIO4, 




























VZ95   VHL4, n=2 45%
VZ96   VHL3, n=2 44%
VZ97   VHL3, n=4 39%
VZ98   VHL4, n=4 46%
VZ117 VHL2, n=2 17%




















2.2.2.5 Synthesis of PROTACs recruiting CRL4CRBN and CRL4DCAF15 
In this paragraph, the synthesis of molecules recruiting CRBN (VZ109 and VZ110, Scheme 
7) and DCAF15 (VZ89 and VZ90, Scheme 7) is reported. Compounds 34 and 35 (Scheme 4) 
were used as key intermediates for a HATU-mediated coupling reaction with the proper E3 
ligands (i.e. POMA and Indisulam derivative 21). POMA was provided by Dr Andrea Testa, 
University of Dundee. Compounds VZ89, VZ90, VZ109 and VZ110 were purified by 
preparative HPLC and obtained in good yields (Scheme 7). 
 
Scheme 7. Synthesis of compounds VZ89, VZ90, VZ109 and VZ110 
 
Reagents and conditions: (a) POMA or Indisulam derivative, HATU, HOAt, DIPEA, DMF, 



































































2.2.3 Biological evaluation of first-generation of PROTACs 
The biological evaluation of first-generation compounds in cell-based assays is reported in the 
following section.  
 
2.2.3.1 Antibodies evaluation  
In order to evaluate the quality, the specificity and the ability in picking up a good signal for 
the protein of interest, BRD9 and BRD7 specific antibodies were tested by western blotting 
using lysates from both HeLa and U2OS cancer cells (Figure 17A).  
For this experiment, HeLa and U2OS cells were seeded in 10 cm dishes with 2.2x106 cells per 
dish in 10 mL media in order to achieve 85-90% confluence before lysing. In preparing samples 
for loading into gels, the proteins of interest needed to be released through chemical and/or 
mechanical methods and protease inhibitors should be added to prevent proteolysis and 
denaturation. Due to the nature of our target proteins, two cell lysis methods were evaluated: 
Ripa buffer (RB) and nuclear extraction (NE).  
Radio-immunoprecipitation assay (Ripa) buffer (RB) derives its name from the original 
application for which it was developed, and it is a mixture of three non-ionic and ionic 
detergents to break membranes. NE is a chemical and physical method useful for studying 
molecules that interact with the nucleus such as transcription factors which bind to DNA. The 
solution used in NE is made of Ripa buffer supplemented with MgCl2, EDTA and benzonase. 
NE involves also the use of ultrasonic processer (sonicator) which produces microbubbles of 
samples before removal of the insoluble fraction by centrifugation. Cells were lysed using both 
methods. Then, different concentrations of the soluble fractions (20, 30 and 40 µg) were run 
by SDS-PAGE on polyacrylamide gels followed by western blot using specific antibodies to 
probe for BRD9 and BRD7 proteins (Figure 17A). The results showed quite specific antibodies 
for the target proteins, as no unspecific bands were detected (Figure 17A). A better band 
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intensity was detected in correspondence of the HeLa cell lysates compared to U2OS, probably 
due to the difference in protein abundance between the two cell lines, as reported in the Human 
Protein Atlas (HPA) database. No particular difference in quality was noticed between the 
samples obtained using RB or NE lysis methods. A good signal was already detectable in the 
presence of 20 µg of total cell lysate in HeLa cells. For the next experiments, it was decided to 
use 30 µg of total cell lysate to ensure a good signal and to use RB as lysis method because 
milder and faster than NE.  
Since the different expression levels of E3 ligases might influence PROTAC activities, we 
explored the protein levels in three cell lines (HeLa, Hek293 and RI-1; Figure 17B). RI-1 cells 
were included in the study because sensitive to BRD9 inhibition/degradation80,127 and of clinical 
relevance. Indeed, RI-1 were assigned to ABC-like lymphoma subtype (activated B-cell) of 
DLBCL, the most aggressive type of non-Hodgkin lymphoma. Protein levels of CRBN and 
VHL were evaluated. Unfortunately, no anti-DCAF15 antibody could be found via commercial 
sources. Different concentrations of the soluble fractions (20, 30 and 40 µg) for each cell line 
were run by SDS-PAGE on polyacrylamide gels followed by Western Blot using specific 
antibodies to probe for CRBN and VHL proteins (Figure 17B). The results were analysed and 
it was observed that CRBN and VHL protein abundance was comparable between the three 
cell lines (Figure 17B). Of note, slightly less band intensity was detected in correspondence of 
RI-1 cell lysates compared to the HeLa and Hek293 (Figure 17B). A good signal was already 




Figure 17. Expression levels of protein evaluation. A) Western-blot analysis of BRD9 and 
BRD7 expression level in HeLa and U2OS. B) Western-blot analysis of CRBN and VHL 
expression level in HeLa, Hek293 and RI-1. 20, 30 and 40 µg of soluble protein fractions were 
loaded for each cell line. 
 
2.2.3.2 BRD7 and BRD9 siRNA experiments 
To confirm the reliability of BRD7 and BRD9 antibodies and to be sure that the band decrease 
belonged to the protein of interest, BRD7 and BRD9 siRNAs were performed in HeLa cells 
(Figure 18). For this experiment, HeLa cells were seeded in 6 well plates with a density of 
0.3x106 cells per plate in 2 mL media in order to achieve 85-90% confluence the day of lysis. 
Cells were treated with decreasing concentrations of siRNA (from 20 nM to 1.25 nM) and 
negative control (NC). Knockdown of both proteins was achieved after 48 h of treatment. After 
cell lysis, the samples were resolved by SDS-PAGE followed by immunoblotting, using the 
corresponding antibodies to probe for the protein of interest. Since BRD7 blots showed two 
bands, two types of gels were run to increase separation and to better understand which band 
was the right one. In 4-12% Bis-Tris gradient pre-casted gels BRD7 correspond to the lower 
band, instead in 6% Bis-Tris homemade gels it is the upper one. The results confirmed a correct 




Figure 18. BRD7 and BRD9 siRNA in HeLa cells. Western-blot analysis of BRD9, BRD7 
and b-actin after transfection with siRNA targeting BRD7 (blot on the right) and BRD9 (blot 
on the left) and negative control (N.C.) siRNA for 48 h. siRNA concentration from 1.25 to 20 
nM.  
 
The same assay was performed in RI-1 cells. Unfortunately, the silencing of BRD7/9 was not 
achieved with specific siRNAs in RI-1 cells, despite testing both after 48 h (Figure 19) and 72 
h (data not shown). The negative result was probably due to the difficulty to transfect these 
suspension cells with cation lipid mediated transfection. It could be useful to repeat the 
experiment using a physical transfection method, like electroporation, that uses an electrical 
pulse to create temporary pores in cell membranes through which substances like nucleic acids 
can pass into cells. An alternative approach to knockdown BRD7 and BRD9 proteins should 






Figure 19. BRD7 and BRD9 siRNA in RI-1 cells. Western-blot analysis of BRD9, BRD7 
and b-actin after transfection with 20 nM of siRNA targeting BRD7 and BRD9 and negative 
control (N.C.) siRNA for 48 h.  
 
2.2.3.3 First-generation compound screening 
In a first experiment, we investigated BRD7/9 degradation by recruiting different E3 ubiquitin 
ligases (i.e. VHL, CRBN, DCAF15), comparing compounds characterized by same BRD7/9 
ligand and linkers (Figure 20). VZ48 and VZ52 (Table 1, Scheme 4) were chosen to recruit 
VHL, VZ109 and VZ110 (Table 2, Scheme 7) to hijack CRBN, VZ89 and VZ90 (Table 3, 
Scheme 7) for DCAF15. HeLa cells were treated with 1µM of compounds at two time points 
(4 h and 16 h) before harvesting. CRBN-based degrader VZ109 and VZ110 showed strong and 
preferential degradation of BRD9 already after 4 h of treatment. These data confirmed the 
strong activity of CRBN-recruiting PROTACs reported by Remillard et al.80 while this research 
was underway. Conversely, VHL-based compounds as well as indisulam-based PROTACs 




Figure 20. Screening of VZ48, VZ52, VZ109, VZ110, VZ89 and VZ90. Western-blot 
analysis of BRD9, BRD7 and b-actin after treatment of HeLa cells with 1 µM of compounds 
for 4 h and 16 h before harvesting. Degradation activity is reported below each lane as % of 
protein abundance relative to 0.1% DMSO vehicle. Intensity values are quantified as described 
in the experimental section.  
 
Then, we decided to profile all first-generation compounds for BRD9 and BRD7 to assess their 
cellular activity. The six PROTACs tested in Figure 20 were included as reference compounds. 
A first-line screening was performed in HeLa cells treated with compounds at fixed 
concentration of 1µM in DMSO at two time points (4 h and 16 h) before harvesting (Figure 
21). The samples, obtained after treatment and cell lysis, were resolved by SDS-PAGE 
followed by Western Blot using corresponding antibodies to probe for BRD9 and BRD7. 
Dimethylsulfoxide (DMSO vehicle, 0.1% v/v) and BI-7273107 (BRD9 inhibitor) were used as 





Figure 21. Screening of first generation of compounds in HeLa cells. Western-blot analysis 
of BRD9, BRD7 and b-actin after treatment of HeLa cells with 1 µM of compounds for 4 h 
(blot on the left) and 16 h (blot on the right) before harvesting. Degradation activity is reported 
below each lane as % of protein abundance relative to 0.1% DMSO vehicle. Intensity values 
are quantified as described in the experimental section.  
 
Compound VZ109 showed almost complete BRD9 degradation after 4-h treatment (Figure 21). 
Compound VZ95 demonstrated marked depletion (around 90%) of BRD9 already after 4 h of 
treatment in HeLa (Figure 21). Furthermore, the replacement of an oxygen with a methylene 
group strongly effected BRD9 degradation after 4-h treatment (compare VZ55 with DAT152). 
Indeed, around 60% of BRD9 degradation was obtained after treatment with VZ55 (Figure 
21). For given matched pairs, compounds with shorter linkers showed higher degradation level 
(VZ95 vs VZ98; VZ96 vs VZ97; VZ48 vs DAT152, VZ52 and VZ49). Moreover, amongst 
conjugates derivatized at the phenolic position of the VHL ligand, the functional groups on the 
LHS of VHL ligand played a key role for the activity. Compounds bearing the fluoro-
cyclopropyl moiety (VHL4) were more potent than those with cyano-cyclopropyl (VHL3) and 
acetyl group (VHL2). All compounds demonstrated preferential degradation on BRD9 over 
BRD7. 
The first-generation compounds were also screened in Hek293 and RI-1 cells to assess 
consistency of the cellular effect in different cell lines which could exhibit different expression 
levels of BRD7 and BRD9 proteins (Figure 22 and 23). The BRD9 degradation profile of first-
generation compounds was similar (even if less pronounced) in Hek293 compared to HeLa 
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(Figure 21 and 22). VZ109 was the most active compound showing more than 80% of BRD9 
depletion, while VZ95 demonstrated around 50% of BRD9 degradation after 16 h (Figure 22). 
Quantification of BRD7 proved to be difficult due to the broad bands. 
 
 
Figure 22. Screening of first generation of compounds in Hek293 cells. Western-blot 
analysis of BRD9, BRD7 and b-actin after treatment of Hek293 cells with 1 µM of compounds 
for 4 h (blot on the left) and 16 h (blot on the right) before harvesting. Degradation activity is 
reported below each lane as % of protein abundance relative to 0.1% DMSO vehicle. Intensity 
values are quantified as described in the experimental section.  
 
RI-1 cells were treated with 1 µM of compounds for 2 and 8 h before lysis (Figure 23). Shorter 
time points were chosen compared HeLa and Hek293 cells due to the sensitivity of BRD9 
depletion in lymphoma cells. The results confirmed the superior activity of CRBN-based 
compounds (VZ109 and VZ110) followed by the VHL-based degrader VZ95 (Figure 23). 
VZ109 and VZ110 induce complete degradation of BRD9 already after 2-h treatment, while 




Figure 23. Screening of first generation of compounds in RI-1 cells. Western-blot analysis 
of BRD9, BRD7 and b-actin after treatment of RI-1 cells with 1 µM of compounds for 2 h (blot 
on the top) and 8 h (blot on the bottom) before harvesting. Degradation activity is reported 
below each lane as % of protein abundance relative to 0.1% DMSO vehicle. Intensity values 
are quantified as described in the experimental section.  
 
2.2.3.4 Time-dependency evaluation VZ55, VZ95 and VZ109 
The best compounds identified from the first line screen were profiled for their cellular 
activities over time. HeLa and Hek293 cells were treated with VZ55, VZ95 and VZ109 (1 µM 
concentration) at the desired time points using dimethylsulfoxide (DMSO, 0.1% v/v) as 
negative vehicle (Figure 24).  
The results obtained were consistent with those observed in the previous experiments. 
Degradation in HeLa cells was more pronounced than in Hek293. A possible explanation could 
be different permeability of these compounds through the cellular membrane and the different 
protein expression levels in the two cell lines. Compound VZ109 was confirmed to be the most 
active compound in HeLa, decreasing BRD9 level by nearly 90% already after 30 min and 
almost complete depletion was reached after 4 h treatment. Conversely, VZ95 induced 70% of 
degradation after 2 h treatment, resulting in an apparent half-life of 3.5 h (Figure 25). Some 
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degradation of BRD9 was also observed for VZ55, albeit only around 40% after 24 h; based 
on these results, we decided to drop VZ55 for further investigation moving forward. Moreover, 
the results of the degradation assay showed consistent selectivity on BRD9 over BRD7.  
 
Figure 24. Time dependency evaluation of compounds VZ55, VZ95 and VZ109. Western-
blot analysis of BRD9, BRD7 and b-actin after treatment of HeLa (blot on the left) and Hek293 
(blot on the right) with 1 µM of compounds at the desired time points before harvesting. 
Degradation activity is reported below each lane as % of protein abundance relative to 0.1% 
DMSO vehicle. Intensity values are quantified as described in the experimental section.  
 
 
Figure 25. Compound VZ95 induces rapid degradation of BRD9 in HeLa cells. 
Quantification of BRD9 protein levels after treatment of HeLa with 1 µM of VZ95 through 24 
h. Intensity values and half-live were quantified as described in the experimental section. 
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2.2.3.5 Concentration-dependency experiment of VZ95 and VZ109 
Compounds VZ95 and VZ109 were further characterized by profiling their concentration-
dependent activity in HeLa and Hek293 cells at early time points, 30 min and 4 h before lysis 
(Figure 26). Both compounds induced preferential degradation of BRD9 over BRD7 in a 
concentration-dependent manner, with higher activity at higher concentration. PROTAC VZ95 
induced more than 60% of degradation of BRD9 at 1 µM after 4 h, while maximal degradation 
(Dmax around 80%) was reached at 10 µM (Figure 26). The calculated half-degrading 
concentration (DC50) was 560 nM against BRD9 after 4 h (Figure 27). At high concentrations 
VZ95 preferentially acted as inhibitor over degrader. This known effect is described as “hook 
effect”:90 at high PROTAC concentrations binary complexes (Target protein:PROTAC and 
E3Ligase:PROTAC) are preferentially formed and compete and ultimately overcome 
formation of the ternary complex. 
VZ109 confirmed to be the most active compound inducing more than 70% of BRD9 
degradation at 100 nM after 4 h and reaching maximal degradation (Dmax) at 10 µM (Figure 26).  
VZ95 emerged to be approximately 10-fold less activity than VZ109 as it needed more time 
to reach a comparable decrease of intensity of the BRD9 band. Indeed, at 1 µM of VZ95 more 
than 60% of depletion of BRD9 was reached after 4 h treatment, while the same degradation 
rate was obtained after 30 min when cells were treated with VZ109.  
Consistent with previous observations, the degradation activity of BRD9 was less pronounced 
in Hek293 cells (Figure 26). VZ95 induced maximal BRD9 degradation (around 40%) at 10 
µM, while more than 90% of depletion of BRD9 level was obtained with 10µM of VZ109 after 




Figure 26. Concentration dependency evaluation of compounds VZ95 and VZ109. 
Western-blot analysis of BRD9, BRD7 and b-actin after treatment of HeLa (blot on the left) 
and Hek293 (blot on the right) with six different concentration at 30 min and 4 h before 
harvesting. Degradation activity is reported below each lane as % of protein abundance relative 




DC50 VZ95 (4h) = 560 nM 
DC50 VZ109 (4h) = 45 nM 
Figure 27. Quantification of BRD9 protein level. HeLa cells were treated with six different 
concentrations of VZ95 and VZ109 at 30 min and 4 h before harvesting. Intensity values and 











B R D 9  d e g  H e L a
















V Z 9 5  4 h
V Z 9 5  3 0  m in
V Z 1 0 9  4 h
V Z 1 0 9  3 0  m in
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2.3 Summary first-generation of compounds 
The first generation of compounds allowed the identification of VZ95 as a novel VHL-based 
PROTACs targeting BRD9 protein. Following a first-line screening in different cancer cell 
lines, compound VZ95 was further characterized by profiling its cellular activity in a 
concentration-dependent evaluation and over time. CRBN-recruiting PROTAC VZ109 
demonstrated the strongest degradation activity confirming the results disclosed by Remillard 
et al.80 Nevertheless, we focused our attention to VHL-recruiting PROTACs which could 
provide advantages compared to PROTACs recruiting CRBN, known to exhibit off-target 


















2.4 Design, synthesis and biological evaluation of second-generation degraders 
The discovery of VZ95 as VHL-based degrader of BRD9 prompted the design of a second 
generation of PROTACs with the goal to further improve degradation activity. In the next 
paragraphs, the design, synthesis and biological evaluation of second-generation compounds 
targeting BRD7 and BRD9 proteins will be described.  
 
2.4.1 Design of second generation of compounds 
The design of the second generation of BRD7/9-targeting PROTACs was guided by the early 
structure-activity relationship emerged from the first-generation molecules. The new 
generation compounds comprised three sets of molecules. Two of those were based on VZ95 
by keeping constant the VHL ligand (namely, VHL4) whereas the linker length and 
composition, as well as the substitution and conjugation chemistry at the BRD7/9 portion were 
changed. In the third set of derivatives, a different derivatization point on BRD7/9 moiety was 
identified and VHL1 was selected as VHL ligand. 
 
2.4.1.1 Type of linkers 
Linkers characterized by different ratios between hydrophilic and lipophilic portions were 
explored. Varying the balance between hydrophilicity and lipophilicity might not only affect 
cell permeability but also influence the conformational equilibria and intrinsic folding 
propensity of the linker, with direct impact on the process of ternary complex formation. 
Therefore, linkers with different lengths (i.e. 5, 8, 11 and 14 atoms) and number of oxygen 
atoms were employed. 
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2.4.1.2 Design of BrdL1/2- Linker-VHL4 PROTACs (first set) 
As previously reported, the design strategy was to keep fixed the VHL4 moiety (VHL ligand) 
and to hijack BRD7/9 protein with BrdL1 (as first generation) along with its analogue BrdL2 
(Table 4). Based on the SARs of BRD7/9 bromodomain inhibitors developed by Martin et al.,107 
we reasoned to arrange the methoxy groups on the phenyl ring in either meta (BrdL1 - as first 
generation) or para (BrdL2) relative to each other (Table 4). Linkers with various length (5-, 
8- and 11-atoms) and composition (0-, 1-, 2- and 3- oxygen atoms) were used to connect the 
two warheads via tertiary amine bond (Table 4). 
 
Table 4. First set BrdL1/2- Linker-VHL4 
 
Structural features of first-set PROTACs 












VZ222 BrdL2 8 1 

































2.4.1.3 Design of BrdL3/4- Linker-VHL4 PROTACs (second set) 
In the second set of compounds we replaced the piperazine moiety of BrdL1/2 with an azetidine 
group (BrdL3 and BrdL4; Table 5). The azetidine substituent was disclosed by Martin et al.107 
as the best vector to boost potency by addressing the backbone carbonyl of His42. BrdL3/4 
moieties were connected to the linkers via amide bond (Table 5). 
 
Table 5. Second set BrdL3/4- Linker-VHL4 
 
Structural features of second-set PROTACs 




VZ216 BrdL4 5 0 
VZ200 BrdL3 
 
5  1 














































2.4.1.4 Design of BrdL5/6- Linker-VHL4 PROTACs (third set) 
To address the question if the egress point of the linkers on the target ligands would affect the 
activity of degraders, a third set of molecules was designed characterized by different 
derivatization vectors of BRD7/9 and VHL ligand.  
Guided by the SAR of BRD7/9 ligand published by Crawford et al.,108 we replaced the 
pyrimido-pyridinone core of BrdL1-4 with a pyrrolo-pyridinone scaffold (Table 6). Pyrrole 
moiety provided a solvent-exposed vector at position 2 for the attachment of the linkers.108 We 
explored both meta- (BrdL5) and para-substituted (BrdL6) dimethoxy group on the phenyl ring 
(Table 6). As VHL ligand, we replaced VHL4 moiety present in compound VZ95 with VHL1 
(as first generation of degraders). To link the two warheads PEG linkers with 11 and 14 atoms 
were studied (Table 6). 
 
Table 6. Third set of BrdL5/6- Linker-VHL1 
 
Structural features of second-set PROTACs 








VZ194 BrdL6 14  4 






























2.4.2 Synthetic routes of second-generation compounds 
In this chapter, the synthetic procedures to prepare the compounds of the second generation are 
described. It is reported the synthetic routes of BrdL1 analogues, the synthesis of the linkers 
and assembly of the final compounds. 
 
2.4.2.1 Synthesis of BRD7/9 ligands BrdL2-6 
BrdL2 is a BrdL1 analogue with a different dimethoxy substitution pattern on the phenyl ring. 
Its synthesis is similar to that reported for BrdL1 (Scheme 1) using 4-bromo-2,5-dimethoxy- 
instead of 4-bromo-2,6-dimethoxy-benzaldhehyde (Scheme 8). 
 
Scheme 8. Synthesis BrdL2 
 
Reagents and conditions: (a) Boc-piperazine, NaBH(OAc)3, THF, rt, overnight; (b) step 1: 
52, B2pin2, KOAc, Pd(dppf)Cl2, 1,4 dioxane, µw 140 ºC, 40 min; step 2: 4, K2CO3 (aq) are added 
to step 1, µw 120 ºC, 30 min; (c) HCl 4M in dioxane, DCM, rt, 1 h 
 
A similar approach was applied to obtain BrdL3 (57) and BrdL4 (58) warheads (Scheme 9). 
Briefly, compounds 55 and 56 were obtained by reductive amination between 4-bromo-2,6-
dimethoxy- (5) or 4-bromo-2,5-dimethoxy-benzaldhehyde (51) and 3-(Boc-amino)azetidine 
(54) in good yield. Then, Miyaura-Suzuki cross-coupling was conducted between the organic 
























butyloxycarbonyl protecting group in acidic conditions led to the desired compounds 57 and 
58 (Scheme 9). 
 
Scheme 9. Synthesis of BrdL3 and BrdL4 
 
Reagents and conditions: (a) NaBH(OAc)3, THF, rt, overnight; (b) step 1: 55 or 56, B2pin2, 
KOAc, Pd(dppf)Cl2, 1,4 dioxane, µw 140 ºC, 40 min; step 2: 4, K2CO3 (aq) are added to step 1, 
µw 120 ºC, 30 min; (c) HCl 4M in dioxane, DCM, rt, 1 h 
 
The synthesis of BrdL5 (65) and BrdL6 (66) ligands is reported in Scheme 10. In details, 
Miyaura-Suzuki cross-coupling was conducted between 62 (provided by Dr. Testa, University 
of Dundee) and 60 or 61, previously obtained by reductive amination between 4-bromo-2,6-
dimethoxy- (5) or 4-bromo-2,5-dimethoxy benzaldhehyde (51) and dimethylamine in 
quantitative yield. Then, cleavage of tosyl group and hydrolysis of ethyl ester of compounds 
63 and 64 was carried out in basic conditions, affording BrdL5 and BrdL6, respectively. 
 
Scheme 10. Synthesis of BrdL5 and BrdL6 
 
Reagents and conditions: (a) NaBH(OAc)3, NaOAc, AcOH, DCM, rt, overnight; (b) step 1: 
60 or 61, B2pin2, KOAc, Pd(dppf)Cl2, 1,4 dioxane, µw 140 ºC, 40 min; step 2: 62, K2CO3 (aq) 




















5   meta R1=H, R2=OMe
















































63 22% R1=H, R2=OMe
64 31% R1=OMe, R2=H
 60 100% R1=H, R2=OMe






BRDL5 (65) R1=H, R2=OMe






5   meta R1=H, R2=OMe







2.4.2.2 Synthesis of BrdL1/2- Linker-VHL4 PROTACs (first set) 
The first set of molecules bear VHL4 moiety and BrdL1/2 derivatives, connected by linkers 
with different lengths (Scheme 11 and 12). For the synthesis of VZ95 and its analogues, we 
used osmium tetroxide as reagent for Lemieux-Johnson reaction to oxidize a double bond of 
the linker to aldehyde. To circumvent the use of this hazardous reagent, the synthetic protocol 
was modified (Scheme 11 and 12). Briefly, nucleophilic substitution between polyethylene 
glycols 67-69 and bromoacetaldehyde diethyl acetal led to the formation of intermediates 70-
72 in good yields. In details, PEG was deprotonated using a 1 M solution of NaHMDS in THF 
at 0 ºC for 1 h, then a DMF solution of bromoacetaldehyde diethyl acetal was added. The 
reaction mixture was heated at 130 °C in microwave for 2 h in a sealed vial. The use of 
microwave conditions improved the time (2 days with conventional heating) and the yield of 
the reactions. Next, compounds 70-72 and 83 were activated as mesylates to allow nucleophilic 
attack by the phenoxy group of VHL4 scaffold. Conversely, the lipophilic chain 74, obtained 
from ethyl 5-bromovalerate 73, was conjugated to VHL4 via alkylation. Then, the diacetal 
functional groups on 75-78 and 84 were hydrolyzed under acidic conditions to afford the 
corresponding aldehydes which were condensed with BrdL1 or BrdL2 via reductive amination 
(Scheme 11 and 12). 
The final compounds were purified by preparative HPLC in order to obtain compounds of high 








Scheme 11. Synthesis of first set of degraders  
 
Reagents and conditions: (a) PEG, NaHMDS 1M in THF, 0 ºC, 1 h, then bromoacetaldehyde 
diethyl acetal, DMF, 130 ºC µw, 2 h; (b) MsCl, TEA, DCM, rt, 3 h; (c) VHL4, K2CO3, DMF, 
70 ºC, overnight; (d) DIBALH, then MeOH, from -78 ºC to rt, overnight; (e) K2CO3, DMF, 70 
ºC, overnight; (f) HCl 1N, THF (1:1), 50 ºC, 2 h; (g) BrdL1-2, NaBH(OAc)3, TEA, DMF, rt, 
overnight. 
 
Scheme 12. Synthesis of first set of degraders VZ221 and VZ222 
 
Reagents and conditions: (a) PEG, NaHMDS 1M in THF, 0 ºC, 1 h, then 74, DMF, 130 ºC 
µw, 2 h; (b) MsCl, TEA, DCM, rt, 3 h; (c) VHL4, K2CO3, DMF, 70 ºC, overnight; (d) HCl 1N, 
THF (1:1), 50 ºC, 2 h, quant. yield; (e) BrdL1-2, NaBH(OAc)3, TEA, DMF, rt, overnight. 
 
2.4.2.3 Synthesis of BrdL3/4- Linker-VHL4 PROTACs (second set) 
In Scheme 13 is reported the synthesis of second set of degraders bearing BrdL3 and BrdL4 
moieties as BRD7/9 ligands. VHL-linker aldehyde intermediates 79-82 (Scheme 11) and 
aldehyde obtained from 84 (Scheme 12) were oxidized to acid through Pinnick reaction using 
sodium chlorite under mild acidic conditions. Then, HATU-mediated couplings with BrdL3 or 






























75 X=O n=1 87%
76 X=O n=2 79%
77 X=O n=3 53%











BrdL1 VZ166 X=O n=1 16%
           VZ95   X=O n=2 25%
           VZ182 X=O n=3 5%
           VZ185 X=CH2 n=1 24%
BrdL2 VZ167 X=O n=1 4%
           VZ169 X=O n=2 17%
           VZ183 X=O n=3 6%
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Scheme 13. Synthesis of second set of degraders  
 
Reagents and conditions: (a) Na2HPO4, NaClO2, 2-methyl-2-butene, t-BuOH, H2O, rt, 4 h, 
quant. yield; (c) BrdL3-4, HATU, HOAt, DIPEA, DMF, rt, 2 h 
 
2.4.2.4 Synthesis of BrdL5/6- Linker-VHL1 PROTACs (third set) 
The synthesis of the third set of compounds included the assembly of final PROTACs starting 
from some intermediates already published in literature (Scheme 14). First, the linkers bearing 
a carboxylic acid on one end and an azide on the other end, characterized by 3- (92) and 4- (93) 
ethylene glycol units, were connected with the free amine of VHL1 scaffold (synthetized as 
reported in literature48) by amide bond formation using HATU as coupling agent. Then, the 
desired final compounds were obtained after reduction of the azide groups to amine (94 and 
95) followed by coupling reactions with the carboxylic acid present on BrdL5 and BrdL6 

















































BrdL3  VZ200 X=O n=1 12%
            VZ207 X=O n=2 13%
            VZ209 X=O n=3 17%
            VZ215 X=CH2 n=1 18%
BrdL4  VZ201 X=O n=1 17%
            VZ208 X=O n=2 11%
            VZ210 X=O n=3 19%



















































85 X=O n=1 
86 X=O n=2







Scheme 14. Synthesis of third set of degraders  
 
Reagents and conditions: (a) HATU, HOAt, DIPEA, DMF, rt, 2 h; (b) H2, Pd/C, EtOH, rt, 5 
h; (c) BrdL5-6, HATU, HOAt, DIPEA, DMF, rt, 2 h 
 
2.4.2.5 Synthesis of cisVZ185 
Since the trans stereochemistry of the hydroxyl group of the hydroxyproline moiety on VHL 
ligand is essential for the binding to VHL, the inactive negative control cisVZ185 of our best 
compound VZ185 (vide infra section 2.4.3.2) has been synthetized (Scheme 15). The synthetic 
strategy involved the synthesis of cisVHL ligand 100 followed its inclusion in the final 
compound. Briefly, compound 9 (synthesized as reported in Scheme 2) was coupled with N-
Boc-cis-4-hydroxy-L-proline to obtain derivative 96 that after BOC deprotection was coupled 
with Boc-L-tert-leucine to afford intermediate 98. Deprotection and HATU-mediated coupling 
with 1-fluoro-cyclopropanecarboxylic acid led to the desired derivative 100. 
The last steps involved the attachment of the linker and BrdL1 moiety. Thus, the alkylation of 
derivative 100 with alkyl bromide 74 (Scheme 11) led to the diacetal compound 101 that was 
hydrolysed to aldehyde 102 and reacted by reductive amination with BrdL1. The final 



























94 n= 3  39%



















BrdL5   VZ192 n=3 20%
             VZ193 n=4 17%
BrdL6   DAT477 







Scheme 15. Synthesis of cisVZ185 
 
Reagents and conditions: (a) N-Boc-cis-4-hydroxy-L-proline, HATU, HOAt, DIPEA, DMF, 
rt, 1 h; (b) 4M HCl in dioxane, rt, 1.5 h; (d) Boc-L-tert-leucine, HATU, HOAt, DIPEA, DMF, 
rt, 1 h; (d) 4M HCl in dioxane, rt, 1.5 h; (e) 1-fluoro-cyclopropanecarboxylic acid, HATU, 
HOAt, DIPEA, DMF, rt, 1 h; (f) 74, K2CO3, DMF, 70 ºC, overnight; (g) HCl 1N, THF (1:1), 











































































































9 96 66% 97 quant.
98 91%99 quant.100 65%








2.4.3 Biological evaluation of second-generation of PROTACs 
In the following section, the biological evaluation of second-generation compounds in cells is 
reported. The work also includes mechanistic, cytotoxicity evaluation and proteomic 
experiments of selected compounds. 
 
2.4.3.1 Second-generation compounds screening 
In order to assess degradation activity, all compounds of the second generation were screened 
in different cell lines (Figure 28-31). HeLa cells were treated with 1 µM of compounds in 
DMSO at two time points (4 and 16 h) (Figure 28). The lysates were evaluated by 
immunoblotting and the protein levels were monitored by incubation with corresponding 
antibodies to probe for BRD9 and BRD7. Dimethylsulfoxide (DMSO vehicle, 0.1% v/v) was 
used as a negative control. VZ95, the most active VHL-recruiting degrader of the first 
generation, was included as a positive control to allow direct comparison. Several compounds 
(Figure 28) demonstrated efficient degradation (more than 90%) of both BRD7 and BRD9 
already after 4 h of treatment. All compounds demonstrated selective degradation of BRD7/9 
over BRD4, screened to evaluate potential off-target effects (Figure 29). 
 
 
Figure 28. Screening of second generation of degraders in HeLa cells. Western-blot 
analysis of BRD9, BRD7 and b-actin after treatment of HeLa cells with 1 µM of compounds 
for 4 h (blot on the left) and 16 h (blot on the right) before harvesting. Degradation activity is 
reported below each lane as % of protein abundance relative to 0.1% DMSO vehicle. Intensity 




Figure 29. Selectivity evaluation of second generation of degraders for BRD4, BRD7 and 
BRD9. Western-blot analysis of BRD9, BRD7, BRD4 and b-actin after treatment of HeLa 
cells with 1 µM of compounds for 4 h (blot on the right) and 16 h (blot on the left) before 
harvesting.  
 
The same experiments were also performed on Hek293 and RI-1 cell lines, to assess 
consistency of the degradation effect in different cell lines (Figure 30-31). Comparable 
degradation profile between HeLa and Hek293 was observed in decreasing both protein levels. 
Quantification of BRD7 and BRD9 protein levels in Figure 30 has proved to be difficult due 
to the broad bands. Constantly all compounds showed selectivity for BRD7 and BRD9 over 
the analogue BET protein BRD4 (Figure 30).  
 
 
Figure 30. Screening of second generation of degraders in Hek293 cells. Western-blot 
analysis of BRD9, BRD7, BRD4 and b-actin after treatment of Hek293 cells with 1 µM of 
compounds for 4 h (blot on the right) and 16 h (blot on the left) before harvesting. Degradation 
activity is reported below each lane as % of protein abundance relative to 0.1% DMSO vehicle. 
Intensity values quantified as described in the experimental section.  
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The screening in RI-1 cells is showed in Figure 31. In detail, RI-1 cells were treated with 1µM 
of compounds for 2 and 8 h before lysis (Figure 31). After 2 h treatment, compounds VZ166 
and VZ186 demonstrated great activity on BRD9, while VZ185 on BRD7. Instead, after 8 h 
of treatment the most active compounds that induced greatest depletion of BRD7/9 were 
VZ166 and VZ185. In detail, VZ166 induced around 85% of degradation of both proteins, 
while VZ185 showed higher selectivity for BRD7 (95% of degradation) over BRD9 (50% of 
degradation). Compounds VZ166, VZ185 and VZ186 were structure related; in fact, VZ186 
is the analogue of VZ185 with BrdL2 instead of BrdL1, and both differ from VZ166 by the 
absence of one oxygen atom in the linker. 
 
 
Figure 31. Screening of second generation of degraders in RI-1 cells. Western-blot analysis 
of BRD9, BRD7 and b-actin after treatment of RI-1 cells with 1 µM of compounds for 2 h (blot 
on the top) and 8 h (blot on the bottom) before harvesting. Degradation activity is reported 
below each lane as % of protein abundance relative to 0.1% DMSO vehicle. Intensity values 
quantified as described in the experimental section.  
 78 
 
In HeLa and RI-1 cells, VZ166 demonstrated the best cellular activity, followed by VZ185. 
Greater degradation activity was observed for compounds containing meta- (BrdL1 and BrdL3) 
over para- (BrdL2 and BrdL4) substituted dimethoxy groups (Figure 28 and 30). 
Representative examples were the matched pairs VZ166 vs VZ167, VZ95 vs VZ169, VZ185 
vs VZ186.  
 
2.4.3.2 Concentration-dependency experiments of VZ166 and VZ185 
Concentration-dependent profile of VZ166 was studied firstly in HeLa cells treated with six 
different concentrations at 30 min and 4 h after treatment (Figure 32). VZ166 showed 
significant degradation of BRD9 after 4-h treatment at the concentration of 100 nM, achieving 
maximal degradation with 1 µM already after 30 min (Figure 32). Quantification of the BRD7 
and BRD9 protein levels has proved to be difficult due to the blot background.  
 
 
Figure 32. Concentration dependency evaluation of compound VZ166. Western-blot 
analysis of BRD9 and BRD7 after treatment of HeLa with six different concentration at 30 min 
and 4 h before harvesting.  
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Next, we assessed the concentration dependency activity in RI-1 cells of compounds VZ166 
and VZ185 (Figure 33). RI-1 cells were treated with six different concentrations of compounds 
at two time points, 2 h and 8 h (Figure 33). Surprisingly, VZ185 turned out to be the most 
potent compound. Indeed, the apparent weaker degradation activity of VZ185 (Figure 31) is 
explained by the “hook” effect for BRD9 showed at 1 µM, acting preferentially as an inhibitor 
probably due to the high-binding affinity of BrdL1 and/or VHL4 to their respective targets. 
VZ185 demonstrated maximal degradation activity of BRD9 in a concentration range between 
10 and 100 nM, and of BRD7 between 100 nM and 1 µM (Figure 33). Therefore, VZ185 
induced preferential degradation of BRD9 over BRD7, resulting in half-degrading 
concentrations (DC50) of 1.76 nM and 4.5 nM against BRD9 and BRD7, respectively, at the 8 
h time-point (Figure 33). In contrast, VZ166 was approximately 10-fold less active, requiring 
1 µM of compound to induced more than 80% of BRD9 degradation (DC50 around 180 nM) 
and around 60% of BRD7 depletion after 8 h before cell harvesting (Figure 33). 
 
  
Figure 33. Concentration dependency evaluation of compounds VZ166 and VZ185. 
Western-blot analysis of BRD9 and BRD7 after treatment of RI-1 with six different 
concentration at 2 h and 8 h before harvesting. Degradation activity is reported below each lane 
as % of protein abundance relative to 0.1% DMSO vehicle. Intensity values quantified as 





2.4.3.3 Time-dependency experiments 
Due to the “hook effect” of VZ185 at 1 µM (section 2.4.3.1), VZ166 appeared to be the most 
potent degrader in the first screen. So, we decided to confirm its degradation profile over time 
in HeLa cells (Figure 34). HeLa cells were treated with 1 µM of compound at different time 
points. Compound VZ95 was added as reference and the study was extended to VZ167 
(analogue of VZ166) and VZ216 which demonstrated great activity in HeLa first-line 
screening (section 2.4.3.1). The results proved fast and potent degradation induced by VZ166 
(Figure 34). The level of BRD7 and BRD9 decreased of about 90% already after 30 min of 
treatment, reaching maximal degradation after 2 h (Figure 34). No protein recovery was 
observed up to 24 h of treatment.  
 
 
Figure 34. Time dependency evaluation of compounds VZ95, VZ166, VZ167 and VZ216. 
Western-blot analysis of BRD9, BRD7 and b-actin after treatment of HeLa with 1 µM of 
compounds at the desired time points before harvesting. Degradation activity is reported below 
each lane as % of protein abundance relative to 0.1% DMSO vehicle and plotted in the graphs. 
Intensity values are quantified as described in the experimental section.  
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To study the time-dependent degradation of VZ185, RI-1 were treated with 10 and 100 nM of 
compound at the desired time points (Figure 35). The results obtained were consistent with 
those observed in the previous experiments (section 2.4.3.2). Indeed, compound VZ185 was 
confirmed to decrease BRD7/9 levels up to 50% already after 30 min of treatment at 100 nM 
before harvesting, reaching more than 90% of degradation after 4 h of treatment. No recovery 
of both proteins was observed after 48 h of treatment (Figure 35). Moreover, at 10 nM 
concentration, our best compound degraded preferentially BRD9 over BRD7 (Figure 35).  




Figure 35. Time dependency evaluation of compounds VZ185. Western-blot analysis of 
BRD9, BRD7 and b-actin after treatment of RI-1 cells with 10 and 100 nM of compound at 
the desired time points before harvesting. Degradation activity is reported below each lane as 
% of protein abundance relative to 0.1% DMSO vehicle and plotted in the graphs. Intensity 





2.4.3.4 First- and second-generation screening compounds at 4 nM 
With the aim to investigate if other compounds suffered of “hook effect” at 1 µM as VZ185, 
we decided to perform a screening of all compounds (first and second generation) at lower 
concentration. The DC50 of VZ185 guided the design of the experiment. HeLa and RI-1 cells 
were treated with first- and second-generation compounds at 4 nM for 4 h (Figure 36). The 
results demonstrated that none of our compounds proved more potent of VZ185, confirming 
the previous data. 
 
 
Figure 36. Screening of first and second generation of degraders in RI-1 (blots on the left) 
and HeLa (blot on the wright) cells. Western-blot analysis of BRD9, BRD7 and b-actin after 
treatment with 4 nM of compounds for 4 h before harvesting. Degradation activity is reported 
below each lane as % of protein abundance relative to 0.1% DMSO vehicle. Intensity values 
quantified as described in the experimental section. 
 
2.4.3.5 Evaluation of mechanism of action of VZ166 and VZ185 
To gain insights on the mechanism of action of VZ166 and VZ185, we examined the 
involvement of the proteasome and CRL2VHL (Figure 37 and 38). The dependency of PROTAC-
induced protein degradation on CRL2VHL was assessed by inhibition of Cullin2 neddylation. 
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Neddylation inhibition was obtained treating cells with 3 µM of MLN4924 (NAE1 inhibitor) 
3 h before treatment with VZ166 or VZ185. Instead, the reliance of the degradation on the 
proteasome was investigated by 30 min pre-treating cells with the proteasome inhibitor MG132 
(50 µM) or carfilzomib (400 nM). After adding the desired compound at the proper 
concentration, the plates were incubated for further 4 h before lysis. 
VZ166 mechanistic evaluation was performed in HeLa (Figure 37); for VZ185 the experiment 
was carried out in RI-1 cells (Figure 38). Single and combination treatments with DMSO, 
MLN4924, MG132 and desired compound were performed to consider the individual and the 
combined effects of compounds. Unsurprisingly, combined treatment of the active degraders 
with neddylation inhibitor and proteasome inhibitor remarkably suppressed the degradation of 
both BRD7/9 proteins, clearly proving the dependency on proteasome and CRL2VHL (Figure 37 
and 38).  
Moreover, to confirm the involvement of VHL in the mechanism of action, a competition assay 
was performed with VHL inhibitor VH298 (Figure 37 and 38). Cells were pre-treated with 
VH298 inhibitor (100 µM) 30 min before adding the compound of interest. As expected, 
VH298 was able to block the degradation activity (Figure 37 and 38). 
Furthermore, to confirm the importance of trans stereochemistry on the hydroxyl group of the 
hydroxyproline moiety on VZ185 for the binding to VHL, treatment with cisVZ185 was 





Figure 37. Mechanistic characterization of VZ166 mode of action. VZ166 activity is 
proteasome and CRL2VHL-dependent. HeLa cells were treated in two replicates with MG132 or 
carfilzomib, MLN4924, VH298 in presence of absence of VZ166 (1 µM) at desired time points 
before harvesting. Intensity values quantified as described in the experimental section. 
 
 
Figure 38. Mechanistic characterization of VZ185 mode of action. VZ185 activity is 
proteasome and CRL2VHL-dependent. RI-1 cells were treated in two replicates with MG132, 
MLN4924, VH298 in presence of absence of VZ185 (100 nM) at desired time points before 
harvesting.  
 
2.4.3.6 Downstream impact and anti-proliferative activity 
Hohmann et al.127 reported that BRD9 supports AML cell growth by sustaining Myc pathway. 
Indeed, after BRD9 knockdown, Myc was one the most downregulated mRNAs. Therefore, to 
study the downstream impact on cMyc levels in response to protein degradation, we evaluated 
protein level in the same cellular context over time (Figure 39). RI-1 cells were treated with 
VZ185 at 10 and 100 nM at several time points. DMSO vehicle (0.1% v/v) was used as a 
negative control. The BRD4 degrader MZ1, known to induce cMyc depletion, was tested as 
control at 1 µM for 4 and 20 h (Figure 39).65,74 
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Interestingly, VZ185 did not show downstream impact on cMyc up to 48 h of treatment at the 
tested concentrations. Instead, the downstream response with the efficient BRD4 degrader 
MZ1was confirmed in RI-1 cells (Figure 39).65,74  
Furthermore, we explored the possible activation of apoptosis in RI-1 cells measured as 
enhancement of PARP cleavage (Figure 39). PARP is one of the apoptotic markers cleaved by 
cysteine proteases, a group of caspases proteins that play a central role in apoptosis. Compared 
to the control (i.e. DMSO), increased levels of cleaved PARP were observed only after 
treatment with 1 µM of MZ1 already at 4 h before lysis. Treatment with 10 or 100 nM of 
VZ185 up to 48 h did not determine any increasing of cleaved PARP protein levels, suggesting 
any apoptotic activity at the tested concentration.  
 
 
Figure 39. Downstream impact and apoptosis evaluation after treatment with VZ185 and 
MZ1. Western-blot analysis of cMyc, cleaved PARP and b-actin after treatment of RI-1 cells 
with 10 and 100 nM of VZ185 and with 1µM of MZ1 at the desired time points before 
harvesting.  
 
To evaluate possible cytotoxic effects that eventually leads to cell death, we assessed the 
consequences of BRD7/9 degradation on the viability of sensitive cancer cell lines (RI-1, 
MOLM-13 and MV4-11 cells) to BRD9 inhibition. Cell viability experiment in presence of 
VZ185, BRD9 inhibitor BI-7273, MZ1 as reference compound and DMSO as vehicle control 
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was assessed in MOLM13, up to the dosage of 5 µM. The cellular ATP was quantified as signal 
of metabolically active cells after days of treatment using different numbers of cells (3 x 105 
and 1.5 x 105 cells/mL) (Figure 40A-B). In presence of MZ1, viability of cells was affected 
confirming the results reported in literature74 and validating the assay. The antiproliferative 
effect of VZ185 was less pronounced in the tested conditions (Figure 40A-C).  
 
 
Figure 40. Cell viability assay determined using the CellTiter-Glo luminescent assay kit. 
A) and B) MOLM13 treated with MZ1, VZ185, BI-7273 and DMSO for 7 days prior to 
quantification of cell viability; C) MOLM13, RI-1 and MV4-11 treated with VZ185 for 7 days 
prior to quantification of cell viability.  
 
Collaborators at Boehringer Ingelheim assessed cell viability after treatment with VZ185 in A-
204 (malignant rhabdoid tumor) and EOL-1 (acute myeloid eosinophilic leukemia) cells 
(Figure 41). EOL-1 and A-204 cells were chosen because of their sensitivity to BRD9 
inhibition/degradation80,127 and their dependency on an active BAF complex133, respectively. Cell 
viability decreased after treatment with VZ185 in both cell lines with EC50 comparable to 
compound dBRD9 confirming results already published by Remillard et al.80 (Figure 41).  
The poor antiproliferative effect of BI-7273 and VZ185 against MOLM13 cells (Figure 40) 




Figure 41. Cell proliferation activity of VZ185 and dBRD9 assessed in A-204 and EOL-1 
cells for 8 days by collaborators at Boehringer Ingelheim (data provided by Dr Manfred 
Koegl, Teresa Gmaschitz and Corinna Wieshofer). 
 
2.4.3.7 Proteomics experiment of VZ185 and cisVZ185 
Proteomics is a large-scale characterization of the entire protein complement of a cell line, 
tissue, or organism. It is used to investigate when and where proteins are expressed, protein-
protein interactions, post-translational modifications, subcellular locations and involvement of 
proteins in metabolic pathways.  
To investigate the selectivity of VZ185 against BRD7/9 proteins and to evaluate possible off-
target effects, proteomics analysis was conducted in a quantitative and an unbiased manner. 
10-Plex tandem mass tags (TMTs-) labelling method enabled simultaneous identification and 
quantification of protein level from up to 10 different samples.  
Proteomic experiments of VZ185, cisVZ185 and DMSO, as vehicle control, were performed 
in triplicate. After labelling each sample with one of TMT isobaric reagents, all samples were 
pooled together to identify proteins by use of mass spectrometry-based method. 
The protocol includes sample preparation, data acquisition and data analysis (Figure 42). In 
details: 
• RI-1 cells were treated with DMSO (0.1% v/v), VZ185 (100 nM) and cisVZ185 (100 
nM) for 4 h of treatment; 
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• Cells were lysates with 4% SDS- Tris 100 nM (strong conditions) on ice; 
• Amount of proteins was quantified with BCA assay (Bradford interferes with SDS); 
• FASP- Filtered Aided Sample Preparation to completely remove SDS residues; 
• Proteins were digested in peptides through trypsin digestion; 
• Peptide quantification; 
• Tandem Mass Tag (TMT) Labelling (TMT are chemical labels referred to as isobaric 
mass tags); 
• Fractionation: the pooled sample was fractionated into fractions using high pH reverse-
phase chromatography; 
• nLC-MS/MS analysis 
• Data analysis with Maxquant software 
 
 
Figure 42. Isobaric tandem mass tag (TMT) proteomics workflow. 
 
6,273 proteins were quantified in this analysis. Amongst the quantified proteins, BRD7 and 
BRD9 were found to be the only two proteins downregulated after treatment with VZ185 that 
satisfy the criteria for a statistically significant change in abundance: p-value y < 0.001 and 
fold change {x <-20% U x>20%} (Figure 43A and 44). The unaffected levels of other 
bromodomain proteins confirmed the selectivity of VZ185 within the bromodomain protein 
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family. As expected, BRD7/9 proteins were not degraded after treatment with negative control 




Figure 43. Impact of VZ185 (A) and cisVZ185 (B) on the cellular proteome after 
treatment of RI-1 cells with 100 nM of compound for 4 h before lysis. Data plotted as fold 
change (%) versus -log10 of p-value (t-test) for a total of 6273 proteins, expressed as mean of 
the replicates. For quantification see experimental section. 
 
 
Figure 44. Proteomics sample validation. Western-blot analysis of BRD9, BRD7 and b-actin 
after treatment of RI-1 cells in three replicates with DMSO, VZ185 (100 nM) and cisVZ185 






2.5 Summary of second-generation of compounds  
In this section, the development of an effective and highly selective degrader of BRD7/9 
proteins was reported. Starting from a promising compound developed in the first generation, 
the structure-activity relationship guided the improvements in depletion activity of new 
compounds. To confirm potent and rapid degradation activity of VZ185, concentration-
dependent activity and cellular activity over time was assessed. Moreover, we studied the 
functional mechanism, downstream impact and anti-proliferative activity of VZ185. Finally, 
to assess its cellular selectivity for BRD7/9 depletion and to identify possible off-targets, 
multiplexed isobaric tagging mass spectrometry proteomic experiment was performed on 


















In this chapter, I have described the development of new series of PROTACs against BDR7 
and BRD9 proteins by recruitment of VHL E3 ligase, a target-ligase pair previously considered 
unproductive. To date, despite several successful examples of target proteins degraded by 
PROTAC, a general methodology for an efficient design remains unclear. The process for the 
development of active PROTACs can be laborious and unpredictable. Variables that make the 
design challenging are the choice of E3 ligase and target ligands as well as the linkers and the 
conjugation patterns. Availability of small-molecule binders for the protein of interest and for 
the E3 ligase is also strictly necessary. In addition, it remains unclear whether optimal target-
ligase combinations exist and typically an extensive testing of chemical series is required 
before the identification of a cell-permeable, functional degrader. Few examples show that 
PROTACs with same target ligands but either VHL or CRBN E3 ligase ligands can exhibit 
different degradation selectivity and efficacy.74,78–80 In some systems, CRBN-based degraders 
show more active profile than VHL-based molecules. The flexibility of CRBN E3 ligase which 
gives rise to increased accessible Lysine residues for ubiquitination on the target protein could 
be accounted for this behaviour.89,134 In light of these observations, it is reasonable to assume that 
design of VHL-based PROTACs requires more exploration than CRBN-based degraders.  
For a given target, the switch of the hijacked ligase could be beneficial and aid targeted protein 
degradation, even if degradation can be readily obtained by recruiting a given ligase. For 
instance, there might be chemical liabilities on a particular ligase ligand that could be easily 
circumvent by switching to a different molecule. Additionally, the expression and the activity 
of the recruited ligase might vary amongst different cells and tissue types.135 Furthermore, 
resistance mechanisms could arise, for example, from the loss of E3 ligase as demonstrated by 
the correlation between level of CRBN and drug response in MM cell line.136 Finally, CRBN-
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based degraders are known to exhibit off-target depletion of PROTAC-independent factors, as 
IKZF1/3 and GSPT1.80,132  
In light of these considerations, we described the development of two series of PROTACs for 
a ligase-target pair previously deemed unsuitable: VHL E3 ligase and BRD9 protein. VHL-
based degraders can be optimized by systematically varying the linkers, the conjugation 
patterns and monitoring cellular degradation activities. The structure-activity relationship 
guided the optimization of initially unimpressive compounds, leading to a significant 
improvement of degradation activity. Indeed, initially molecules hijacking three different E3 
ligases characterized by different linkers and conjugation patterns were designed. At this stage, 
compounds VZ95 and VZ109 were identified as the best selective BRD9 degraders hijacking 
VHL and CRBN, respectively. Encouraged by the BRD9 degradation activity of the initial 
VHL-based PROTACs (so far considered unproductive), a second round of degraders was 
designed. A wider variety of linkers (including linker from 5 to 11 atoms and different number 
of oxygen atoms) as well as different connecting points and ligands were evaluated.  
The emerged medicinal chemistry study led the discovery of VZ185 which is characterized by 
enhanced target degradation compared to VZ95 and similar to levels achieved with CRBN-
based degrader VZ109, but enabling depletion of BRD7. 
Finally, VZ185 was characterized as potent, selective and fast VHL-based dual degrader with 
slight preference for BRD9 over BRD7 (DC50 of 1.7 nM against BRD9, and of 4.5 nM against 
BRD7). More generally, these SAR studies could be applicable to broadly approach to discover 
effective target-ligase pair previously considered unproductive. The acquired findings qualify 
a new chemical probe that could find wide use in chemical and cell biology to explore BRD7 




3. Targeting Kinase Protein Degradation 
 
3.1 Introduction 
Protein kinases play an essential role in the majority of signal transduction networks that are 
crucial in the regulation of several cellular processes, i.e. cell growth, metabolism, and division, 
transcription and protein cellular localization. Indeed, protein kinases modify the function of 
proteins through phosphorylation. Phosphorylation of a target protein is a reversible process 
that involves the balanced action of protein kinases and phosphatases.137,138 The human genome 
encoded approximately 538 kinases, one of the largest families of human enzymes and genes. 
These proteins share common structural features in the catalytic domains, with consist of 250-
300 amino acids. Their catalytic mechanism uses ATP (or GTP) to generate phosphate 
monoester of protein alcohol (serine or threonine) or phenolic (tyrosine) groups. Therefore, 
two main subfamilies have been classified: the protein-serine/threonine kinases and the 
protein-tyrosine kinases.139 Biochemically, the phosphorylation of an alcohol or phenol group is 
catalysed by protein kinases following the reaction:140 
 
MgATP1− + protein−O : H→ protein−O : PO32− + MgADP + H+ 
 
The main catalytic roles of kinase domains are: i) binding and orientation of the ATP (or GTP) 
phosphate donor as complex with divalent cation (Mg2+ or Mn2+); ii) binding and orientating the 
substrate protein; iii) transfer phosphate from ATP (or GTP) to acceptor hydroxyl residue on 
protein substrate.139  
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On the basis of catalytic domain sequence similarity, Manning et al. have classified eukaryotic 
protein kinases in nine groups (Table 7).137 In the next section, a brief description of some 
protein kinases is reported. 
 
Table 7. Classification of eukaryotic protein kinases. 
Group name # of 
members 
Kinases in the group 
AGC  63 PKA, PKG, PKC families, Akt1/2/3, Aurora kinase, PDK1, RSK1/2/3/4 
CAMK  74 CaMK1/2/4, PhKg1/2, MAPKAPK2/3/5, Nek1-11, MLCK 
CK1  12 CK1, TTBK1/2, VRK1/2/3 
CMGC  61 CDK, MAPK, CDKL 
STE 47 MAPK cascade families 
TK 90 58 receptors (i.e. EGFR, Flt) and 32 non-receptor tyrosine kinases (i.e. Abl, 
JAK, Src) 
TKL  43 MLK1-4, LISK, IRAK, Raf, RIPK, STRK 
RCG 5 Similar to protein-tyrosine kinases 
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3.1.1 Non-receptor tyrosine kinases (NRTKs) 
NRTKs belong to the protein tyrosine kinases (TKs, Table 7) which transfer a phosphate from 
ATP to tyrosine residues on protein substrates. Based on their sequence homology, NRTKs 
have been subdivided into nine families: Abl, Src, Jak, Fak, Csk, Tec, Syk, Fes and Ack. For 
the purpose of this thesis, we will analyse Abl, Src and Jak families. 
 
Abl family 
Abelson tyrosine (Abl) family, consisting of c-Abl and Arg (Abl-related protein), has 
implicated in a range of cellular processes, including regulation of cell proliferation, survival, 
cell adhesion and migration. c-Abl is localized in the nucleus, cytosol, mitochondria, 
endoplasmic reticulum and cell cortex. Deregulation and aberrant expression of c-Abl gene has 
been associated with several types of cancer, such as breast cancer, colon cancer, and non-
small-cell lung cancer. c-Abl is responsible to phosphorylate oncogenic signalling pathways 
by activation of ERK5, Rac/Jnk, and Stat 1/3 pathways.141 Furthermore, c-Abl is also known to 
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be implicated in the genesis of chronic myelogenous leukemia (CML). The responsible 
oncogene is Bcr-Abl, also called Philadelphia chromosome (Ph). This gene is formed after 
translocation and fusion of the Abl proto-oncogene on chromosome 9 to the breakpoint cluster 
region (Bcr) gene on chromosome 22. Several small-molecules inhibitors have been developed 
to target c-Abl and Bcr-Abl with the aim to block their kinase activity (section 3.2).142  
 
Src family 
Src family represents the largest group of NRTKs and is further subdivided into three 
subfamilies: the Lyn-related family, the Src-related family and the the PTK6/Brk- related 
family. The Lyn-related family consists of: Lck/Yes-related tyrosine kinase (Lyn), 
hematopoietic cell kinase (Hck), lymphocyte-specific protein tyrosine kinase (Lck), and B 
lymphocyte kinase (Blk). The Src-related family includes the PTK with oncogenic potential 
Fyn, Yes-related kinase (Yrk), and Yamaguchi sarcoma oncogene (Yes). Finally, the 
PTK6/Brk- related family consists of protein tyrosine kinase 6 (PTK6), also known as breast 
cancer kinase (Brk) and Fyn-related kinase (Frk), also known as Rak- and Src-related kinase 
lacking C-terminal regulatory tyrosine and N-terminal myristylation sites (Srms). Src kinases 
take part to several cellular processes, such as cell growth, differentiation, apoptosis, survival 
and proliferation. Dysregulation of Src has been found in different type of malignancies, such 
as melanoma, breast, colon and lung carcinoma.141  
 
Jak family 
The Janus kinases (Jak) family consists of Jak1, Jak2, Jak3 and tyrosine kinase-2 (Tyk 2). All 
of them comprise two catalytic domains, one of which is inactive. Jak principal activity is the 
phosphorylation and activation of the signal transducers and activators of transcription (Stat) 
factors. Phosphorylated Stat proteins dimerize and translocate into the nucleus. As 
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consequence, expression of genes linked to cellular stress, proliferation and differentiation are 
activated. Jak/Stat pathway has been involved in haematopoiesis, inflammation, and immunity 
response. Moreover, deregulation of Jak activity has been observed in a number of disorders 
including acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), rheumatoid 
arthritis, psoriasis, polycythaemia vera, and myeloproliferative diseases.141  
 
3.1.2 Aurora kinases 
The aurora kinases are protein-serine/threonine kinases, evolutionarily conserved in eukaryotes 
and able to coordinate cell division.143 This family consists of three members: aurora A, B and 
C. These proteins play essential roles in centrosome maturation, mitotic spindle formation, 
chromosome segregation and cytokinesis.144  
Dysregulation of aurora kinase levels have been associates with different types of human 
cancers and therefore have become targets for inhibition of tumor cell division.145,146  
 
3.1.3 c-Kit 
c-Kit is a protein-tyrosine kinase also known as Mast/stem cell growth factor receptor (SCFR) 
or CD117. This proto-oncogene is a receptor tyrosine kinase protein encoded by the KIT gene.147 
c-Kit was first described by the German biochemist Axel Ullrich in 1987 as the cellular 
homolog of the feline sarcoma viral oncogene v-kit.148 Upon binding to stem cell factor (SCF), 
c-Kit is activated leading to its autophosphorylation and initiation of signal transduction. 
Signalling proteins are recruited to activated c-Kit by interaction domains (i.e. SH2 and PTB) 
that specifically bind to phosphorylated tyrosine residues of c-Kit. Activation of c-Kit 
signalling has been found to be important in several cellular processes, for example to mediate 
cell survival, migration, and proliferation. Thereby, signalling from c-Kit is essential for 
normal haematopoiesis, pigmentation, fertility, gut movement, and some aspects of the nervous 
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system. However, c-Kit kinase activity has been found to be deregulated in diseases such 
cancer and allergy. It has been observed that mutations in c-Kit can promote tumor formation 
and progression, thereby, therapeutics agents targeting this receptor have been developed. 
Furthermore, also downregulation of c-Kit has been associated to pathologic conditions, 
namely piebaldism.149  
 
3.1.4 Mek1/2 and P44/42 MAPK Kinases 
Mek1/2 and P44/42 MAPK are two protein kinases that take part to the same signalling 
pathway. The MAPK/ERK pathway, also known as the Ras-Raf-MEK-ERK pathway, is a 
cascade of signals which includes many proteins, including MEK and MAPK, also called ERK 
(extracellular signal-regulated kinases). MEK1/2 are serine/tyrosine/threonine kinase proteins, 
while MAPK is a serine-threonine kinase protein. Both proteins are mitogen-activated protein 
kinases. Upon binding of a signalling molecule to the receptor on the cell surface, proteins 
communicate the signal to the DNA in the nucleus to produce cellular responses, such as 
protein expression or cell division. Regulation of MAPK/ERK pathway is crucial for cell cycle 
entry promoting cell growth and proliferation. Instead, deregulation of this pathway has been 
associated with the promotion of tumor cell growth of a variety of cancers.150 
 
3.2 Protein kinases as targets for pathologic conditions 
Mutations and dysregulation of protein kinases has been associated with human diseases, 
including carcinogenesis, immune, neurological and infectious diseases.151–154 In light of these 
observations, these enzymes have become interesting drug targets in the last years. Since the 
development of the first protein kinase inhibitor, in the early 1980s, 35 kinase inhibitors have 
received FDA approval, 31 of which for treatment of malignancies such as breast and lung 
cancer (Figure 45).155 In addition to small-molecule inhibitors, kinase-targeted antibodies, have 
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demonstrated efficacy in cancer treatment, for example transtuzumab in breast cancer and 
cetuximab in colorectal and head/neck cancer.156,157  
The breakthrough occurred in 2001 when imatinib, a phenyl-amino-pyridine derivative, was 
approved for the treatment of CML. Later on, several molecules have been approved for 
treatment of imatinib-resistant tumor and other various malignancies. In addition to the 
approved kinase inhibitors, there are more than 3000 ongoing Phase I-III clinical studies for 
hundreds of new molecules.155  
Despite the encouraging results, many challenges are associated with drug resistance, 
selectivity, toxicity and efficacy, confusing the clinical efficacy of these molecules.140  
For the purpose of this thesis, imatinib dasatinib and nilotinib inhibitors will be described in 
the next section. 
 
 
Figure 45. Timeline of key events in the development of protein kinase inhibitors  
 
3.2.1 Tyrosine kinase inhibitors (TKIs): overview of imatinib, dasatinib and nilotinib 
In the last years, several TKIs have been developed to block the ATP-binding site and inhibit 
autophosphorylation of the tyrosine residues of proto-oncogenes. Thereby, intracellular signal-
transduction pathways were inhibited in tumor cells, leading to deregulation of key cellular 
activities.158,159  
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Imatinib mesylate, also known as Gleevecâ (STI571), was the first commercially available TKI 
(Figure 46). It has been approved for the treatment of CML and gastro-intestinal stromal tumors 
(GISTs).160 Imatinib is a phenyl amino pyrimidine derivative that blocks, upon binding, the 
catalytic domain of different oncogenic tyrosine kinases, including Bcr-Abl, c-Kit, PDGFR 
(platelet-derived growth factor receptor), CSF-1R (colony-stimulating factor receptor-1) and 
DDR (discoidin domain receptor).161  
Despite the success of imatinib as human cancer drug, many patients developed polyclonal 
resistances due to mutations in the Bcr-Abl domain. To overcome these limitations, a second-
generation of TKIs was developed, including dasatinib (Sprycelâ, BMS-354825) and nilotinib 
(Tasignaâ, AMN107) (Figure 46). Both compounds were more potent than first-generation 
TKIs and were employed for the treatment of imatinib-resistant tumors. In details, dasatinib is 
highly active against Bcr-Abl, Src- and Btk-family kinases, PDGFR, c-Kit and ephrin-A2 
receptor. Nilotinib is a potent inhibitor of Bcr-Abl, c-Kit, CSF-1R, amongst others.162,163  
 
 




































3.3 Aims and objectives 
Multiple mutations of different genes are responsible of oncogenic transformations. Increased 
tyrosine kinase activity results in a loss of cell cycle control and cell proliferation, leading to 
human cancer initiation and progression. Moreover, dysregulation of kinases has been 
associated with others human disorders, such as infectious, neurological and immune diseases. 
In the last years, several small-molecules inhibitors have been successfully developed to target 
cancer-specific molecules and signalling pathways. However, despite the peculiarities of 
small-molecules inhibitors (i.e. ADME properties), the employ of these agents is associated 
with side-effects and drug resistance. With the aim to overcome limitations of inhibition, we 
have decided to employ PROTAC strategy to degrade protein kinases of interest. 
This one-year project has been carried out at Nerviano Medical Sciences (NMS), under the 
supervision of Dr Eduard Felder. Starting from a proof of concept already published in 
literature, we designed, synthesised degraders targeting other protein kinases. The biological 













3.4 Design of bifunctional small molecules targeting protein kinases 
Protein kinases are amongst the key players of the cellular functions by transferring a phosphate 
group to a protein. Moreover, recent works have elucidated that protein kinase dysregulation 
occurs in many diseases including cancer and inflammatory disorders. We therefore became 
interested in the opportunity to degrade these targets using PROTAC approach.  
Firstly, we planned to study a literature example to confirm the proof of concept with the 
prospect of extending the development of PROTACs to other targets. Among the available 
molecules, compound DAS-6-2-2-6-CRBN, developed by Lai et al,79 was chosen. This 
molecule induces degradation of c-ABL and BCR-ABL oncogenic tyrosine kinase via 
recruitment of CRL4CRBN  (Figure 47). This compound bears CRBN ligand (pomalidomide) and 
tyrosine kinase inhibitor (dasatinib precursor) connected by a linker. The connecting chain was 
linked to pomalidomide (amine at C-4) and dasatinib (piperazine nitrogen) in solvent exposed 
moieties not involved in key interactions with proteins. The linker is characterized by 19-atom 
length and two ethylene glycol units between two hexamethylene chains. 
Based on DAS-6-2-2-6-CRBN,79 we designed VZ-6-2-2-6-POMA aiming to induce 
degradation of serine/threonine kinases (Figure 47). This molecule bears pomalidomide 
(POMA) to recruit CRBN and an aminopyrazole kinase inhibitor to target the protein of 
interest. Same linker and attachment points of DAS-6-2-2-6-CRBN were chosen to connect 
the target ligands. 
Furthermore, to address the question if the linker length and composition could affect the 
degradation, we designed DAS-6-2-2-2-POMA and DAS-6am-2-2am-6-POMA, sharing with 
VZ-6-2-2-6-POMA the derivatization points but characterized by linkers with different 
hydrophobic and hydrophilic properties (Figure 47). In details, DAS-6-2-2-2-POMA bears a 
shorter linker (14 atoms, 3 oxygen) whereas, DAS-6am-2-2am-6-POMA is characterized by 
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the same linker length of DAS-6-2-2-6-CRBN but two oxamethylene units were replaced with 
two amide bonds.  
 
 
Figure 47. Structures of PROTACs designed to recruit protein kinases at one side and 
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3.5 Synthetic routes to protein kinase-targeting compounds 
The desired compounds were obtained through a convergent synthetic strategy, which involved 
the preparation of the target protein ligands (i.e. pomalidomide and dasatinib precursor) and 
the linker chains, which were then assembled. 
 
3.5.1 Synthesis of Pomalidomide 
The synthesis of pomalidomide can be divided into three parts: synthesis of the glutarimide 
ring, synthesis of the phthalimide ring and the assembly of the two parts (Figure 48).164 
Thalidomide known for its teratogenic and immunosuppressive effects is marketed as a racemic 
mixture, although it has been suggested that the teratogenic effects are associated with the (S)-
isomer and the sedative hypnotic effect is associated with the (R)-isomer. Follow this 
statement, pomalidomide, thalidomide derivative, has been synthetized and reported as racemic 
mixture as well, since studies about exact mechanism of action remain elusive and they are 
beyond the scope of this thesis.  
 
 
Figure 48. Structure of Pomalidomide. 
 
The glutarimide ring was prepared by a two-step approach, starting from the commercially 
available Boc-L-glutamine. As shown in Scheme 16, treatment of Boc-L-glutamine (104) with 










led to 105 in 59% yield. The BOC protecting group was subsequently cleaved by TFA at rt to 
afford the glutarimide derivative 106 as TFA salt in quantitative yield.  
 
Scheme 16. Synthesis of glutarimide ring. 
 
 
Then, the phthalimide ring was synthetized starting from the commercially available 3-
nitrophthalic acid (107, Scheme 17). Compound 107 was heated in acetic anhydride for 30 min 
affording 3-nitrophthalic anhydride (108) in 89% yield. The condensation between glutarimide 
ring 106 and 108 in glacial acetic led to compound 109 in 58% yield. Reduction of the nitro 
group by transfer hydrogenation was carried out with NaH2PO2*H2O and Pd/C 10% in THF, 
affording the desired compound 110 in 84% yield. 
 
Scheme 17. Synthesis of phthalimide ring and final compound pomalidomide (110). 
 
 
Probably due to the high presence of salt residues accumulated in the reduction step by transfer 
hydrogenation, compound 110 was characterized by a low NMR purity (32%). So, to increase 
the purity of 110 (Figure 48), a new route was employed (Scheme 18). As reported in the 
literature,165 the reaction between 4-nitrophthalic anhydride 108 and 106 in the presence of TEA, 













































intermediate 111 in methanol was hydrogenated (50 psi) in the presence of Pd/C 10% at rt for 
30 min to yield the reduced intermediate that, without further purification, was refluxed in 
methanol for 2 h to yield the desired product 110 in 37% yield and with a 96% NMR purity.  
 
Scheme 18. Alternative synthesis of Pomalidomide (110). 
 
 
3.5.2 Synthesis of Dasatinib derivative 
The synthesis of dasatinib (Figure 49) was carried out according to the procedure already 
published in literature.166 
 
 
Figure 49. Structure of Dasatinib derivative. 
 
Briefly, the commercially available compound 112 (Scheme 19A) was hydrolysed to the acid 
derivative 113 (82% yield), converted into the corresponding acyl chloride and coupled with 
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disappointing result was presumably due to the difficulty of 2-chloro-6-methylaniline to act as 
a good nucleophile, because of the steric hindrance of the 2,6-disubstitution. 
To overcome this problem, a more efficient approach was followed (Scheme 19B).167 This route 
involved a chemoselective α-bromination of β-ethoxyacrylamide followed by a one-pot 
treatment with thiourea to give the desired compound 119 in good yield. Moreover, another 
advantage of this approach would be the elimination of the protection and deprotection steps 
needed in the previous synthesis. In details (Scheme 19B), condensation between ethyl vinyl 
ether 115 and oxalyl chloride 116 led to the β-ethoxy acryloyl chloride 117 which, as crude 
material, was condensed with 2-chloro-6-methylaniline to afford 118 in 60% yield. The yield 
of 118 was marginally affected using a distilled batch of 117168 (60% with crude 117 vs 50% 
with distilled 117). Compound 118 was treated with NBS and then with thiourea to afford 
compound 119 in 65% yield. No N-bromination or phenyl ring bromination by-products were 
isolated under these reaction conditions. Successively, 119 was treated with 4,6-dichloro-2-
methylpyrimidine 120 in the presence of t-BuONa as base keeping the temperature between 0 
°C and rt to limit the formation of side-product 6-chloro-N-(2-chloro-6-methylphenyl)-2-
methylpyrimidin-4-amine. The desired product 121 was obtained in 62% yield. Aromatic 
nucleophilic substitution was achieved treating 121 with piperazine in 1,4-dioxane, under 
microwave conditions (at 120 °C for 1 h) and using DIPEA as base, which led to the final 








Scheme 19. Synthesis of Dasatinib derivative.  
 
3.5.3 Synthesis of the linkers 
3.5.3.1 Linker -6-2-2-6- 
 
 
Figure 50. Structure of linker -6-2-2-6- coupled with target ligand (TL) and 
pomalidomide (CRBN lig) 
 
Initially, we planned to build up DAS-6-2-2-6-CRBN79 by “growing” the linker attached to the 
pomalidomide end, in order to minimize the difficulties of handling and monitoring PEG 
analogues derivatives not UV visible. Thus, 6-bromoexanoic acid (123, Scheme 20) was 
activated as acidic chloride (124) to allow acylation of 110, using DIPEA as base. As result a 
mixture of 6-bromo- and 6-chloro-hexanoyl derivatives (125) was obtained in 56% yield. 
Compounds 125 were then converted into the iodo-derivative 126 applying Finkelstein reaction 
(yield: 51%). 
Intermediates 125 or 126 were used to explore nucleophilic substitution of the halide by 
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and TBAHS as phase-transfer catalyst. Both reactions failed probably due to decomposition of 
the starting material or the final product. 
 
Scheme 20. Synthesis: growing the linker attached to pomalidomide (110). 
 
 
Because of these poor results, we decided first to synthetize the linker and then attach it to 
CRBN ligand as an alternative synthetic strategy (Scheme 21 and 22). Intermediate 133 was 
obtained by two strategies, which required or not the mono-protection of diethylene glycol with 
a trityl group (Scheme 21 and 22).  
Multifunctional compounds as synthons present several synthetic challenges. Therefore, mono-
protection of water-soluble substrates containing multiple hydroxyl groups is a fundamental 
requirement for their correct functionalization in multistep reaction sequences.169 As shown in 
Scheme 21, a 10-fold excess of diethylene glycol 128 was reacted with trityl chloride in the 
presence of dry pyridine acting as base and solvent. Microwave irradiation at 80 °C for 30 min 
led to a mixture of mono- and bis-tritylate (129, 130). The formation of bis-tritylated side 
product has been avoided by lowering the temperature to 50 °C, affording only 129 in 74% 






















































Scheme 21. Synthesis of compound 133 
 
 
Table 8. Reaction conditions and yields of diethylene glycol 
Method T °C 129- yield 130- yield 
A 80 28% 20% 
B 50 74% 0% 
 
The reaction between 129 and 131, previously obtained by tosylation of 6-chloroexanol,170 was 
studied evaluating different conditions (Scheme 21, Table 9). The most convenient method 
involved a biphasic system (water-toluene) in the presence of TBAHS, used as phase-transfer 
catalyst in stoichiometric amount, and NaOH as a base (method F, Table 9). In these conditions 
132 was obtained in 82% yield. 
The cleavage of the trityl group to obtain 133 (Scheme 21) can be carried out using either TES, 
TFA in DCM (procedure A, yield: 26%) or 1,4-cyclohexadiene, Pd/C 10% in MeOH, 80-90 
°C under conventional and microwave heating (procedure B, yield: 35%). Despite the lower 
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Table 9. Evaluated conditions for the reaction between 129 and 131. 
Method Reagents T °C Time Yield 
A NaOH/H2O, TBAB, Toluene rt 7 dd 52% 
B NaOH/H2O, TBAB, Toluene MW 60 °C 1 h  21% 
C NaH, THF rt 15 dd failed 
D NaOH/H2O, TBAB MW 140 °C 30 min failed 
E NaOH/H2O, TBAB MW 100 °C 1 h 76% 
F NaOH/H2O, TBAHS, Toluene rt overnight 82% 
 
To avoid the mono-protection step of diethylene glycol, the synthesis of 133 was also tried by 
direct reaction between 128 and 131 or 135, previously obtained by tosylation or mesylation 
of 6-chloroexanol 134 (Scheme 22).170 Out of the different evaluated reaction conditions (Table 
10), the use of the mesylate 135 and NaH in DMF/THF (1:1) granted the higher yield of the 
desired compound 133.  
 
Table 10. Evaluated conditions for the reaction between 128 and 131 or 135. 
Method Reagents T °C Time Yield 
A NaOH, 15-crown-5, THF 0 °C -rt overnight failed 
B KOH, H2O/DMSO 0 °C to rt overnight 17% 
C NaH, DMF/THF (1:1) 0 °C to rt overnight 43% (with 135) 23% (with 131) 
 
The final step of the synthetic procedure involved the condensation of 133 with tert-butyl-6-
bromohexanoate (136), prepared from 6-bromohexanoic acid 123 and Boc2O and DMAP in 
93% yield. Differently from the literature data,79 the condensation between 133 and 136 led 
directly to the unprotected 5-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethoxy) pentanoic acid 137 
(37% yield).  
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Scheme 22. Synthesis of linker 137 (-6-2-2-6-)  
 
 
3.5.3.2 Linker -6-2-2-2- 
 
 
Figure 51. Structure of linker -6-2-2-2- coupled with target ligand (TL) and 
pomalidomide (CRBN lig) 
 
The linker -6-2-2-2- (Figure 51) was synthesized by reacting intermediate 133 (Scheme 21 and 
22) and tert-butyl-2-bromoacetate (138) in the presence of NaH in a 1:1 mixture of DMF/THF 
(Scheme 23). The desired compound 139 was obtained in 44% yield.  
 



















































3.5.3.3 Linker -6am-2-2am-6- 
 
 
Figure 52. Structure of linker -6am-2-2am-6- coupled with target ligand (TL) and 
pomalidomide (CRBN lig) 
 
Linker -6am-2-2am-6- (Figure 52) is characterized by 19-atom chain bearing a bis-amide 
functionality. The synthetic strategy included two different approaches. The first one dealt with 
the synthesis of the linker, which was then coupled with the appropriate ligands. The second 
one involved the synthesis of the desired product by “growing” the linker on pomalidomide, 
as already reported for the synthesis of compound DAS-6-2-2-6-CRBN (see section 3.5.3.1). 
The first approach involved the coupling between intermediates 142 and 144 (Scheme 24). 142 
was synthesized by reaction between diglycolic anhydride 140 and 6-amino-1-hexanol 141 in 
THF in low yield (9%). This disappointing result was probably due to the low solubility of 141 
in THF and also to the high solubility of the final product in water used for work-up. 
Investigation of the same reaction by using different solvents, such as DMSO, DCM, 
mesitylene, or t-amyl alcohol was carried out without yield improvement. Therefore, we set up 
a different approach: reaction between 140 and 141 in DMSO afforded the acid that was 
converted to the corresponding methyl ester using TMSCHN2, diethyl ether and methanol (62% 
yield). Finally, the hydrolysis of the ester intermediate using LiOH and a mixture of 
THF/H2O/MeOH (2:1:2) led to 142 in quantitative yield.  
Esterification of 6-(boc-amino)caproic acid (143) was obtained using (trimethylsilyl) 
diazomethane (TMSD, 2M solution in hexane) in a mixture 1:1 diethyl ether/methanol. TMSD 
was added dropwise until the solution became persistently pale yellow (Scheme 24). After 










yield. The last step involved the coupling between 142 and 144, using EDC, TEA in DCM. 
Unfortunately, the reaction failed, and future studies will evaluate other coupling reaction 
conditions, such as HATU, HOAt or HOBt (Scheme 24). 
 
Scheme 24. Synthesis of linker -6am-2-2am-6 (145) 
 
 
The second approach (Scheme 25), started with amide coupling of 110 with 6-(Boc-
amino)caproic acid 143, performed with phosphorus oxychloride in pyridine at -15 °C for 30 
min, that led to 146 in 84% yield. Treatment of 146 with TFA in DCM cleaved the protecting 
group in quantitative yield (147). We also tried using 4M HCl in dioxane, but the reaction was 
very slow. Derivative 148 was obtained in 23% yield after reaction between 147 and 142 
(prepared as reported in Scheme 24), using EDC and HOBt as coupling reagents and DIPEA 
as base in DMF.  
Successively, 148 was activated as mesylate (93% yield) and condensed with the dasatinib 
precursor 122, stirring the mixture at rt for 48 h using NMP as solvent and DIPEA as base. The 
reaction was followed by HPLC-MS where we observed only two peaks, one for compound 
122 and the other one with final product +18, due to the presence of water, often seen in this 
type of compounds. Then the solvent was evaporated with HT12 evaporator and the crude was 
washed with ether. The crude was purified by HPLC purification. Unfortunately, the 1H-NMR 
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the dasatinib mesylate precursor. The molecular weight tricked us because MW of dasatinib 
mesylate precursor is 522 and in HPLC it is seen as dimer (522 x 2 = 1044; M+1 = 1045). The 
molecular weight of the dimer (M+1) is the same of DAS-6-2am-2am-6-POMA +18. This 
side reaction was probably due to residues of methansulphonyl chloride, so that the mesylation 
of the piperazine was favored over the nucleophilic attack between 122 and 149. 
 
Scheme 25. Synthesis: growing the linker -6am-2-2am-6- attached to pomalidomide 
 
 
3.5.4 Assembly of final PROTACs bearing linker -6-2-2-6- 
In order to obtain DAS-6-2-2-6-CRBN we followed the procedure already published with 
minor changes.79 The method published employed activation of the carboxylic acid with thionyl 
chloride in toluene followed by coupling with pomalidomide. This method yielded the desired 
product 151 in 5% yield after overnight stirring. With the aim to improve the yield and to 
reduce the reaction time, an alternative reaction condition was then tried (Scheme 26). The acid 
linker 137 was activated with phosphorus oxychloride in pyridine (essential to catalyse 





































































































the amino group of pomalidomide. Reaction reached completion within 30 min and the desired 
product 151 was obtained in higher yield (11%).  
Successively, Finkelstein reaction yielded 152 (89%) which was used for nucleophilic 
substitution of the halide by dasatinib precursor (122), heating at 80 °C overnight, using NMP 
as solvent and DIPEA as base. NMP was used instead of DMF (used in the literature79) to avoid 
the possible reaction of dimethylamine with the alkyl iodide. DAS-6-2-2-6-CRBN (153) was 
obtained in 95% yield after purification by preparative HPLC. 
 
Scheme 26. Synthesis of DAS-6-2-2-6-CRBN 
 
Intermediate 152 was used also for the synthesis of the new PROTACs VZ-6-2-2-6-POMA 
(Scheme 27). The nucleophilic substitution of the halide 152 by aminopyrazole kinase inhibitor 
(154) was carried out at rt stirring overnight, using DIPEA as base and NMP as solvent. NMP 
was evaporated with HT12 evaporator and the product was suspended with ether. VZ-6-2-2-6-
POMA (155) was purified by preparative HPLC and the final compound was obtained in 28% 
yield.  
 














































Scheme 27. Synthesis of VZ-6-2-2-6-POMA 
 
 
3.5.5 Assembly of final PROTAC bearing linker -6-2-2-2- 
To obtain PROTAC DAS-6-2-2-2-6-POMA, linker 139 was first coupled with pomalidomide 
110 and consequently with dasatinib precursor 122. As shown in Scheme 28, after hydrolysis 
of 139 with TFA and DCM, the corresponding acid was activated as acyl chloride refluxing 
the acid with thionyl chloride in THF. Then, the obtained acyl chloride was coupled with 110 
in THF under reflux for 4 h to afford the desired product 156 in 84% yield after column 
purification. Finkelstein reaction yielded 157 (88% yield) that was then condensed with the 
122, stirring the mixture at room temperature for 24 h, using NMP as solvent and DIPEA as 
base. The solvent was evaporated with HT12 evaporator and the crude was suspended with 
ether and the final product was obtained in 89% yield after HPLC purification. 
 

































































































3.6 Biological evaluation of protein kinase-targeting compounds 
In the following section, the cellular evaluation of the synthesized protein kinase-targeting 
compounds is described. The experiments were carried out by the Department of Biology of 
NMS. 
 
3.6.1 Biological evaluation of DAS-6-2-2-6-CRBN 
In order to confirm the data of cellular activity already published,79 DAS-6-2-2-6-CRBN was 
tested for c-ABL and BCR-ABL degradation in cell culture. K562 cells, human chronic 
myelogenous leukemia (CML) cell line, were treated with different concentrations of DAS-6-
2-2-6-CRBN (NMS-P836). Dimethylsulfoxide (DMSO) and dasatinib (1 µM, tyrosine kinase 
inhibitor) were used as control. After 8 h and 24 h of treatment the samples were resolved by 
SDS-PAGE and the protein abundance was analysed by Western-Blot using antibodies to probe 
for c-ABL and BCR-ABL proteins (Figure 53). DAS-6-2-2-6-CRBN showed a clear 
degradation of c-ABL already after 8 h of treatment with 100 nM of compound. It also induced 
reduction in protein abundance of BCR-ABL already after 8 h of treatment at 250 nM, but 
maximum effect was registered after 24 h of treatment. The apparent decrease of both protein 
degradation observed at high concentration was due to the “hook effect”, characterized by the 
formation of binary complexes (protein of interest-compound and CRBN-compound) rather 
than ternary complex (protein of interest-compound-CRBN).79 Our data were in line with Lai 




Figure 53. Evaluation of c-ABL and BCR-ABL degradation in K562 cells treated with 
different concentrations of compound DAS-6-2-2-6-CRBN (NMS-P836) for 8 h and 24 h 
before harvesting. DMSO and dasatinib were used as control. 
 
To assess degradation activity of compound over others tyrosine protein kinases, DAS-6-2-2-
6-CRBN was then tested for Src, Yes, Lck, Jak2, Mek1/2 and P44/42 MAPK proteins in K252 
cells treated for 24 h (Figure 54). DMSO and dasatinib (1 µM, tyrosine kinase inhibitor) were 
used as control. DAS-6-2-2-6-CRBN demonstrated visible depletion of Src, Yes and Lck 
proteins already at the concentration of 25 nM, whereas no degradation of Jak2, Mek1/2 and 




































































Figure 54. Evaluation of Src, Yes, Lck, Jak2, Mek1/2 and P44/42 MAPK degradation in 
K562 cells treated with different concentrations of compound DAS-6-2-2-6-CRBN (NMS-
P836) for 24 h before harvesting. DMSO and dasatinib were used as control. 
 
DAS-6-2-2-6-CRBN activity was also evaluated in GIST-882 cells, gastrointestinal stromal 
tumor cell line, bearing an activated form of KIT protein (Figure 55). DMSO and dasatinib (1 
µM, tyrosine kinase inhibitor) were used as control. After treatment with different 
concentration of compound for 24 h, c-KIT and P-p44/42 MAPK were probed using the 
corresponding specific antibodies. The results showed strong degradation of P-p44/42 MAPK 
already at 1 µM.  
 
 
Figure 55. Evaluation of c-KIT and P-p44/42 MAPK degradation in GIST-882 cells 
treated with different concentrations of compound DAS-6-2-2-6-CRBN (NMS-P836) for 
24 h before harvesting. DMSO and dasatinib were used as control. 
 
3.6.2 Biological evaluation of DAS-6-2-2-2-POMA 
To evaluate if DAS-6-2-2-2-POMA degrader could induce c-ABL, BCR-ABL, Scr and Yes 
depletion, protein abundance of these proteins was evaluated. K562 cells were treated with 










56). DMSO and dasatinib (1 µM, tyrosine kinase inhibitor) were used as control. DAS-6-2-2-
2-POMA demonstrated strong degradation of c-ABL, Src and Yes at concentrations as low as 
25 nM. Moreover, at high concentration (10 µM) “hook effect” was noticed. However, some 
degradation of BRC-ABL was also observed.  
 
 
Figure 56. Evaluation of c-ABL, BCR-ABL, Src, Yes degradation in K562 cells treated 
with different concentrations of compound DAS-6-2-2-2-POMA (NMS-P324) for 24 h 
before harvesting. DMSO and dasatinib were used as control. 
 
3.6.3 Biological evaluation of VZ-6-2-2-6-POMA 
In order to assess cellular activity of VZ-6-2-2-6-POMA (NMS-P180), levels of c-ABL, BCR-
ABL and Aurora A proteins were evaluated in K562 cells (Figure 57). DMSO and VZ reference 
(1 µM) were used as control. After 24 h of treatment with different concentration of compound 
and cell lysis, samples were resolved by electrophoresis followed by Western blot. VZ-6-2-2-
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6-POMA showed selective degradation of Aurora A protein over c-ABL and BCR-ABL. In 




Figure 57. Evaluation of c-ABL, BCR-ABL and Aurora A degradation in K562 cells treated 
with different concentrations of compound VZ-6-2-2-6-POMA (NMS-P180) for 24 h before 
harvesting. DMSO and VZ reference were used as control.  
 
Furthermore, the selectivity of VZ-6-2-2-6-POMA (NMS-P180) to induce Aurora A 
degradation over Aurora B was studied (Figure 58). In details, the human ovarian carcinoma 
A2780 cells were treated with different concentration of compound for 24 h. The results 
showed preferential degradation of Aurora A. Instead, depletion of Aurora B was less 
pronounced and only appreciated at higher concentration (1-2 µM more than 50%). Moreover, 
to evaluate if the inhibition and degradation of Aurora proteins could have an impact on 
phosphorylation of Ser10 on histone H3, levels of this protein were evaluated in A2780 cells 
 122 
(Figure 58). Indeed, it was observed that treatment with aurora kinase inhibitor (VZ reference) 
led to inhibition of histone H3 phosphorylation. Similar impact was detected after treatment 
with 2-10 µM of VZ-6-2-2-6-POMA degrader. This effect also confirmed the mechanism of 
action of Aurora B to induce phosphorylation of Ser10 on histone H3.  
 
 
Figure 58. Evaluation of Aurora A and B degradation and levels of P-H3 (Ser10) in A2780 
cells treated with different concentrations of compound VZ-6-2-2-6-POMA (NMS-P180) 
for 24 h before harvesting. DMSO and VZ reference were used as control. 
 
3.7 In silico activities 
Linker length and composition play a key role in PROTAC efficacy, since these factors are 
supposed to allow optimal interaction between target protein, E3 ligase and PROTAC, in order 
to achieve efficient ubiquitination of the target protein and its ultimate degradation. However, 
 123 
at the moment, linker features for optimal ternary complex formation remain rather empirical. 
Hence, in order to generate a preliminary model and gain experience with its applicability, an 
in silico study of the ternary complex formation was carried out. DAS-6-2-2-6-CRBN was 
taken as reference compound, trying to find out the best distance for a PROTAC hooking ABL 
and CRBN. 
X-ray crystal structure of dasatinib (BMS-354825) bound to activated ABL Kinase domain 
(PDB code: 2GQG) and that of pomalidomide bound to DDB1-CRBN (PDB code: 4CI3) were 
used as model components. The approach started with ab initio geometry optimization of DAS-
6-2-2-6-CRBN structure conformation. Two minimized conformations were chosen, a V-
shaped structure and an extended conformation of DAS-6-2-2-6-CRBN (Figure 59). The 
optimized structures were then transferred to the dedicated software (Discovery Studio 
Visualizer). Pomalidomide and dasatinib structures were superimposed over their original 
crystal structure, maintaining linker conformation as in the ab initio optimization. 
Superimposition a V-shaped structure of DAS-6-2-2-6-CRBN in the ternary complex results 
in negative steric interactions of ABL (blue) and CRBN (light blue) (Figure 60A). In the second 
case, using an extended optimized conformation of DAS-6-2-2-6-CRBN, the negative 















Figure 60. In silico ternary complex formation. 
 
Applying this method, we generated a small library of ternary complexes that could be a 
starting point to make some consideration about correlation of biological activity and 
conformation. Additionally to DAS-6-2-2-6-CRBN, the studied PROTACs were DAS-6-5-6-
CRBN, DAS-6-2-2-CRBN, DAS-6-2-2-2-2-2-2-CRBN published by Lai et al.,79 and the two 
new PROTACs DAS-6-2-2-2-POMA and DAS-6am-2-2am-6-POMA (Figure 61). 
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In summary, in this section we reported the design, the synthesis and biological 
characterization of PROTACs targeting protein kinases. The aim of this project was to study a 
literature example to confirm a proof of concept. Amongst those available, we chose DAS-6-
2-2-6-CRBN, based on a potent tyrosine kinase inhibitor and CRBN ligand that induce 
degradation of c-ABL and BCR-ABL. After synthesis of DAS-6-2-2-6-CRBN, its cellular 
activity was assessed in cells. As expected, our results were consistent with those already 
published. Furthermore, we decided to extend the development of degraders focusing on how 
target ligand and linker composition affect efficacy and selectivity. Based on the same target 
ligands of DAS-6-2-2-6-CRBN, we designed two compounds with different linkers: DAS-6-
2-2-2-POMA characterized by a shorter linker and DAS-6-2am-2am-6-POMA bearing a di-
amide functionality. Only DAS-6-2-2-2-POMA was successfully synthesized and biologically 
characterized. It demonstrated pronounced degradation of c-ABL, Src and Yes proteins.  
The last bifunctional molecule was developed to address the question if other protein kinases 
could be degraded. So, we designed a degrader VZ-6-2-2-6-POMA based on an aminopyrazole 
kinase inhibitor targeting seronine/threonine protein kinases. It showed preferential 
degradation of Aurora A already at 250 nM after 24 h of treatment. Moreover, it degraded 
Aurora B at high concentration, leading to inhibition of phosphorylation of histone H3.  
 
 
 
 
 
